[
    {
        "filename": "abbvie-s-shares-rise-as-1st-qtr-financials-beat-expectations.json",
        "title": "AbbVie's shares rise as 1st-qtr financials beat expectations",
        "description": "AbbVie's shares rise as 1st-qtr financials beat expectations",
        "link": "https://www.thepharmaletter.com/article/abbvie-s-shares-rise-as-1st-qtr-financials-beat-expectations",
        "pubDate": "2021-04-30 16:31:00"
    },
    {
        "filename": "gilead-shares-hit-as-sales-figures-miss-estimates.json",
        "title": "Gilead shares hit as sales figures miss estimates",
        "description": "US biotech major Gilead Sciences was trading more than 1% lower after an hour\u00e2\u0080\u0099s trading on Friday following the presentation of its first quarter financial resu",
        "link": "https://www.thepharmaletter.com/article/gilead-shares-hit-as-sales-figures-miss-estimates",
        "pubDate": "2021-04-30 15:18:00"
    },
    {
        "filename": "vertex-reports-strong-1st-qtr-sales-growth.json",
        "title": "Vertex reports strong 1st-qtr sales growth",
        "description": "Vertex reports strong 1st-qtr sales growth",
        "link": "https://www.thepharmaletter.com/article/vertex-reports-strong-1st-qtr-sales-growth",
        "pubDate": "2021-04-30 14:39:00"
    },
    {
        "filename": "european-submission-for-covid-19-vaccination-in-children.json",
        "title": "European submission for COVID-19 vaccination in children",
        "description": "The first coronavirus vaccine for older children could soon be available in Europe, after Pfizer and BioNTech submitted to broaden the Conditional Marketing Aut",
        "link": "https://www.thepharmaletter.com/article/european-submission-for-covid-19-vaccination-in-children",
        "pubDate": "2021-04-30 14:22:00"
    },
    {
        "filename": "mood-music-changes-as-fda-panel-gets-tough-on-early-i-o-nods.json",
        "title": "Mood music changes as FDA gets tough on early I-O nods",
        "description": "After two days of discussions yielding reaffirmed support for Tecentriq\u00e2\u0080\u0099s (atezolizumab) Accelerated Approvals, the US regulator\u00e2\u0080\u0099s scientific panel changed tack",
        "link": "https://www.thepharmaletter.com/article/mood-music-changes-as-fda-panel-gets-tough-on-early-i-o-nods",
        "pubDate": "2021-04-30 13:11:00"
    },
    {
        "filename": "create-an-agile-regulatory-framework-and-maintain-a-strong-incentives-system-says-efpia-in-eu-roadmap-comments.json",
        "title": "Create an agile regulatory framework and maintain a strong incentives\u00e2\u0080\u0099 system, says EFPIA in EU roadmap comments",
        "description": "The European Federation of Pharmaceutical Industries and Associations (EFPIA) has filed its response to the European Union (EU) roadmap/IIA on the Evaluation an",
        "link": "https://www.thepharmaletter.com/article/create-an-agile-regulatory-framework-and-maintain-a-strong-incentives-system-says-efpia-in-eu-roadmap-comments",
        "pubDate": "2021-04-30 12:47:00"
    },
    {
        "filename": "us-fda-approval-for-hikma-s-kloxxado.json",
        "title": "US FDA approval for Hikma\u00e2\u0080\u0099s Kloxxado",
        "description": "US FDA approval for Hikma\u00e2\u0080\u0099s Kloxxado",
        "link": "https://www.thepharmaletter.com/article/us-fda-approval-for-hikma-s-kloxxado",
        "pubDate": "2021-04-30 12:22:00"
    },
    {
        "filename": "advances-in-the-pharmacological-treatment-of-rare-multiple-sclerosis-variants.json",
        "title": "Advances in the pharmacological treatment of rare multiple sclerosis variants",
        "description": "Advances in the pharmacological treatment of rare multiple sclerosis variants",
        "link": "https://www.thepharmaletter.com/article/advances-in-the-pharmacological-treatment-of-rare-multiple-sclerosis-variants",
        "pubDate": "2021-04-30 11:06:00"
    },
    {
        "filename": "soriot-s-ship-stays-the-course-in-first-quarter.json",
        "title": "Soriot's ship stays the course in first quarter",
        "description": "Markets welcomed a robust first quarter results statement from AstraZeneca, with the firm reporting revenues of $7.3 billion, an increase of 15% on the same per",
        "link": "https://www.thepharmaletter.com/article/soriot-s-ship-stays-the-course-in-first-quarter",
        "pubDate": "2021-04-30 10:40:00"
    },
    {
        "filename": "uk-s-mhra-approves-xeris-ogluo.json",
        "title": "UK\u00e2\u0080\u0099s MHRA approves Xeris\u00e2\u0080\u0099 Ogluo",
        "description": "UK\u00e2\u0080\u0099s MHRA approves Xeris\u00e2\u0080\u0099 Ogluo",
        "link": "https://www.thepharmaletter.com/article/uk-s-mhra-approves-xeris-ogluo",
        "pubDate": "2021-04-30 10:37:00"
    },
    {
        "filename": "positive-results-of-phase-iii-clinical-trial-of-velphoro-in-china.json",
        "title": "Positive results of Phase-III clinical trial of Velphoro in China",
        "description": "Positive results of Phase-III clinical trial of Velphoro in China",
        "link": "https://www.thepharmaletter.com/article/positive-results-of-phase-iii-clinical-trial-of-velphoro-in-china",
        "pubDate": "2021-04-30 10:05:00"
    },
    {
        "filename": "fda-issues-another-crl-this-one-to-leo-pharma.json",
        "title": "FDA issues another CRL, this one to LEO Pharma",
        "description": "FDA issues another CRL, this one to LEO Pharma",
        "link": "https://www.thepharmaletter.com/article/fda-issues-another-crl-this-one-to-leo-pharma",
        "pubDate": "2021-04-29 16:11:00"
    },
    {
        "filename": "merck-co-comes-up-short-in-sales-and-earnings.json",
        "title": "Merck & Co comes up short in sales and earnings",
        "description": "US pharma major Merck & Co became the latest drugmaker to announce disappointing, pandemic-hit first quarter financial results, sending shares in the company do",
        "link": "https://www.thepharmaletter.com/article/merck-co-comes-up-short-in-sales-and-earnings",
        "pubDate": "2021-04-29 14:40:00"
    },
    {
        "filename": "bigger-bristol-myers-powers-ahead-in-first-quarter.json",
        "title": "Bigger Bristol Myers powers ahead in first quarter",
        "description": "Bristol Myers Squibb matched analysts\u00e2\u0080\u0099 revenue forecasts for the first quarter, reporting $11.1 billion in global sales, and an earnings per share (EPS) figure ",
        "link": "https://www.thepharmaletter.com/article/bigger-bristol-myers-powers-ahead-in-first-quarter",
        "pubDate": "2021-04-29 14:26:00"
    },
    {
        "filename": "protalix-shares-plummet-by-44-on-crl-news.json",
        "title": "Protalix shares plummet by 44% on CRL news",
        "description": "Shares in Protalix BioTherapeutics closed 44% lower on Wednesday after the firm and its partner Chiesi Farmaceutici announced receipt of a Complete Response Let",
        "link": "https://www.thepharmaletter.com/article/protalix-shares-plummet-by-44-on-crl-news",
        "pubDate": "2021-04-29 13:01:00"
    },
    {
        "filename": "global-medicine-spending-to-reach-1-6-trillion-in-2025.json",
        "title": "Global medicine spending to reach $1.6 trillion in 2025",
        "description": "Global medicine spending to reach $1.6 trillion in 2025",
        "link": "https://www.thepharmaletter.com/article/global-medicine-spending-to-reach-1-6-trillion-in-2025",
        "pubDate": "2021-04-29 12:47:00"
    },
    {
        "filename": "moderna-aims-to-make-three-billion-doses-of-coronavirus-vaccine.json",
        "title": "Moderna aims to make three billion doses of coronavirus vaccine",
        "description": "Cambridge, USA-based mRNA specialist Moderna is investing in manufacturing facilities to boost global supplies of its coronavirus vaccine in 2022.",
        "link": "https://www.thepharmaletter.com/article/moderna-aims-to-make-three-billion-doses-of-coronavirus-vaccine",
        "pubDate": "2021-04-29 12:39:00"
    },
    {
        "filename": "pfizer-expands-anti-infectives-pipeline-with-acquisition.json",
        "title": "Pfizer expands anti-infectives pipeline with acquisition",
        "description": "Pfizer expands anti-infectives pipeline with acquisition",
        "link": "https://www.thepharmaletter.com/article/pfizer-expands-anti-infectives-pipeline-with-acquisition",
        "pubDate": "2021-04-29 11:48:00"
    },
    {
        "filename": "pharnext-updates-on-pxt3003-for-patients-with-cmt1a.json",
        "title": "Pharnext updates on PXT3003 for patients with CMT1A",
        "description": "Pharnext updates on PXT3003 for patients with CMT1A",
        "link": "https://www.thepharmaletter.com/article/pharnext-updates-on-pxt3003-for-patients-with-cmt1a",
        "pubDate": "2021-04-29 11:10:00"
    },
    {
        "filename": "more-i-o-early-approvals-bear-scrutiny-of-fda-review.json",
        "title": "More I-O early approvals bear scrutiny of FDA review",
        "description": "There was more good news for Swiss company Roche on Wednesday, as the US regulator\u00e2\u0080\u0099s scientific panel voted to maintain another Accelerated Approval for Tecentr",
        "link": "https://www.thepharmaletter.com/article/more-i-o-early-approvals-bear-scrutiny-of-fda-review",
        "pubDate": "2021-04-29 10:12:00"
    },
    {
        "filename": "teva-dips-as-it-reports-downturn-on-1st-qtr-sales-and-earnings.json",
        "title": "Teva dips as it reports downturn on 1st-qtr sales and earnings",
        "description": "Teva dips as it reports downturn on 1st-qtr sales and earnings",
        "link": "https://www.thepharmaletter.com/article/teva-dips-as-it-reports-downturn-on-1st-qtr-sales-and-earnings",
        "pubDate": "2021-04-29 10:11:00"
    },
    {
        "filename": "differentiation-and-partnership-key-to-chinese-companies-global-strategy.json",
        "title": "Differentiation and partnership key to Chinese companies\u00e2\u0080\u0099 global strategy",
        "description": "Differentiation and partnership key to Chinese companies\u00e2\u0080\u0099 global strategy",
        "link": "https://www.thepharmaletter.com/article/differentiation-and-partnership-key-to-chinese-companies-global-strategy",
        "pubDate": "2021-04-28 17:07:00"
    },
    {
        "filename": "how-is-healthcare-access-in-southeast-asia-shaping-up-in-2021.json",
        "title": "How is healthcare access in Southeast Asia shaping up in 2021?",
        "description": "A Special Report on the top five trends redefining the way healthcare stakeholders look at long-term healthcare access sustainability in the region from Roshel ",
        "link": "https://www.thepharmaletter.com/article/how-is-healthcare-access-in-southeast-asia-shaping-up-in-2021",
        "pubDate": "2021-04-28 16:57:00"
    },
    {
        "filename": "gsk-sees-sales-slump-due-to-covid-19-disruption.json",
        "title": "GSK sees sales slump due to COVID-19 disruption",
        "description": "Sales and earnings were down at UK drugmaker GlaxoSmithKline (LSE: GSK) in the group\u00e2\u0080\u0099s first quarter financial results, albeit no worse than expected.",
        "link": "https://www.thepharmaletter.com/article/gsk-sees-sales-slump-due-to-covid-19-disruption",
        "pubDate": "2021-04-28 16:19:00"
    },
    {
        "filename": "msd-inks-licensing-pacts-with-5-indian-pharma-companies-for-covid-19-oral-drug-candidate.json",
        "title": "MSD inks licensing pacts with 5 Indian pharma companies for COVID-19 oral drug candidate",
        "description": "MSD inks licensing pacts with 5 Indian pharma companies for COVID-19 oral drug candidate",
        "link": "https://www.thepharmaletter.com/article/msd-inks-licensing-pacts-with-5-indian-pharma-companies-for-covid-19-oral-drug-candidate",
        "pubDate": "2021-04-28 14:37:00"
    },
    {
        "filename": "grifols-to-build-new-r-d-hub-to-work-on-immune-disorders.json",
        "title": "Grifols to build new R&D hub to work on immune disorders",
        "description": "Spanish plasma specialist Grifols is to establish a global R&D hub in Andorra, focused on the human immune system and the potential for novel immune therapies.",
        "link": "https://www.thepharmaletter.com/article/grifols-to-build-new-r-d-hub-to-work-on-immune-disorders",
        "pubDate": "2021-04-28 14:12:00"
    },
    {
        "filename": "tecentriq-approval-on-safer-ground-after-fda-panel-vote.json",
        "title": "Tecentriq approval on safer ground after FDA panel vote",
        "description": "While the US regulator has been taking a hard look at Accelerated Approvals which lack confirmatory data, Tecentriq (atezolizumab) appears set to retain its app",
        "link": "https://www.thepharmaletter.com/article/tecentriq-approval-on-safer-ground-after-fda-panel-vote",
        "pubDate": "2021-04-28 13:41:00"
    },
    {
        "filename": "fda-grants-priority-review-for-nefecon-for-patients-with-igan.json",
        "title": "FDA grants priority review for Nefecon, for patients with IgAN",
        "description": "FDA grants priority review for Nefecon, for patients with IgAN",
        "link": "https://www.thepharmaletter.com/article/fda-grants-priority-review-for-nefecon-for-patients-with-igan",
        "pubDate": "2021-04-28 12:25:00"
    },
    {
        "filename": "pandemic-and-pricing-dent-first-quarter-performance-at-amgen.json",
        "title": "Pandemic and pricing dent first quarter performance at Amgen",
        "description": NaN,
        "link": "https://www.thepharmaletter.com/article/pandemic-and-pricing-dent-first-quarter-performance-at-amgen",
        "pubDate": "2021-04-28 11:45:00"
    },
    {
        "filename": "enzyvant-resubmits-bla-for-pediatric-congenital-athymia-drug.json",
        "title": "Enzyvant resubmits BLA for pediatric congenital athymia drug",
        "description": "Nearly 18 months on from Enzyvant\u00e2\u0080\u0099s receipt of a Complete Response Letter (CRL) relating to its initial Biologics Licensing Application (BLA) for RVT-802, the c",
        "link": "https://www.thepharmaletter.com/article/enzyvant-resubmits-bla-for-pediatric-congenital-athymia-drug",
        "pubDate": "2021-04-28 11:39:00"
    },
    {
        "filename": "sanofi-s-1st-qtr-takes-negative-currency-hit.json",
        "title": "Sanofi\u00e2\u0080\u0099s 1st-qtr takes negative currency hit",
        "description": "Sanofi\u00e2\u0080\u0099s 1st-qtr takes negative currency hit",
        "link": "https://www.thepharmaletter.com/article/sanofi-s-1st-qtr-takes-negative-currency-hit",
        "pubDate": "2021-04-28 11:24:00"
    },
    {
        "filename": "fda-accepts-takeda-s-mobocertinib-for-priority-review.json",
        "title": "FDA accepts Takeda\u00e2\u0080\u0099s mobocertinib for priority review",
        "description": "FDA accepts Takeda\u00e2\u0080\u0099s mobocertinib for priority review",
        "link": "https://www.thepharmaletter.com/article/fda-accepts-takeda-s-mobocertinib-for-priority-review",
        "pubDate": "2021-04-28 10:16:00"
    },
    {
        "filename": "lilly-shares-suffer-on-earnings-miss-and-reduced-forecast.json",
        "title": "Lilly shares suffer on earnings miss and reduced forecast",
        "description": "Eli Lilly (NYSE: LLY) underwhelmed with its first-quarter financial results, sending its share price tumbling by 2% by lunchtime on Tuesday.",
        "link": "https://www.thepharmaletter.com/article/lilly-shares-suffer-on-earnings-miss-and-reduced-forecast",
        "pubDate": "2021-04-27 18:17:00"
    },
    {
        "filename": "pyxis-unveils-ambitions-on-adcs.json",
        "title": "Pyxis unveils ambitions on ADCs",
        "description": NaN,
        "link": "https://www.thepharmaletter.com/article/pyxis-unveils-ambitions-on-adcs",
        "pubDate": "2021-04-27 16:54:00"
    },
    {
        "filename": "logicbio-out-licenses-lb-001-in-greater-china-inks-deal-in-japan.json",
        "title": "LogicBio out-licenses LB-001 in Greater China; inks deal in Japan",
        "description": "LogicBio out-licenses LB-001 in Greater China; inks deal in Japan",
        "link": "https://www.thepharmaletter.com/article/logicbio-out-licenses-lb-001-in-greater-china-inks-deal-in-japan",
        "pubDate": "2021-04-27 16:51:00"
    },
    {
        "filename": "gilead-sciences-to-challenge-compulsory-licensing-of-its-anti-covid-19-drug-in-russia.json",
        "title": "Gilead Sciences challenges compulsory licensing of its anti-COVID-19 drug in Russia",
        "description": "Gilead Sciences challenges compulsory licensing of its anti-COVID-19 drug in Russia",
        "link": "https://www.thepharmaletter.com/article/gilead-sciences-to-challenge-compulsory-licensing-of-its-anti-covid-19-drug-in-russia",
        "pubDate": "2021-04-27 16:15:00"
    },
    {
        "filename": "chiesi-supports-sustainable-inhaler-project.json",
        "title": "Chiesi supports sustainable inhaler project",
        "description": "Family-owned Italian drugmaker Chiesi has teamed up with two small to medium-sized enterprise (SME) companies in an initiative with funding agency Innovate UK t",
        "link": "https://www.thepharmaletter.com/article/chiesi-supports-sustainable-inhaler-project",
        "pubDate": "2021-04-27 14:56:00"
    },
    {
        "filename": "russian-government-to-stimulate-production-of-apis.json",
        "title": "Russian government to stimulate production of APIs",
        "description": "Russian government to stimulate production of APIs",
        "link": "https://www.thepharmaletter.com/article/russian-government-to-stimulate-production-of-apis",
        "pubDate": "2021-04-27 14:04:00"
    },
    {
        "filename": "daiichi-sankyo-links-with-esperion-to-market-bempedoic-acid-in-new-region.json",
        "title": "Daiichi Sankyo links with Esperion to market bempedoic acid in new region",
        "description": "Daiichi Sankyo links with Esperion to market bempedoic acid in new region",
        "link": "https://www.thepharmaletter.com/article/daiichi-sankyo-links-with-esperion-to-market-bempedoic-acid-in-new-region",
        "pubDate": "2021-04-27 12:35:00"
    },
    {
        "filename": "novartis-1st-quarter-financials-miss-expectations.json",
        "title": "Novartis 1st-quarter financials miss expectations",
        "description": "Novartis 1st-quarter financials miss expectations",
        "link": "https://www.thepharmaletter.com/article/novartis-1st-quarter-financials-miss-expectations",
        "pubDate": "2021-04-27 12:00:00"
    },
    {
        "filename": "eu-sues-vaccine-developer-while-usa-donates-excess-supplies.json",
        "title": "EU sues vaccine developer while USA donates excess supplies",
        "description": "As anticipated, the European Union launched a legal action against AstraZeneca in the Belgian courts on Friday, alleging the British firm failed to live up to i",
        "link": "https://www.thepharmaletter.com/article/eu-sues-vaccine-developer-while-usa-donates-excess-supplies",
        "pubDate": "2021-04-27 10:54:00"
    },
    {
        "filename": "gilead-donates-veklury-to-indian-government-assisting-local-production.json",
        "title": "Gilead donates Veklury to Indian government; assisting local production",
        "description": "Gilead donates Veklury to Indian government; assisting local production",
        "link": "https://www.thepharmaletter.com/article/gilead-donates-veklury-to-indian-government-assisting-local-production",
        "pubDate": "2021-04-27 10:22:00"
    },
    {
        "filename": "samsung-biologics-and-tg-therapeutics-expand-collaboration-on-ublituximab.json",
        "title": "Samsung Biologics and TG Therapeutics expand collaboration on ublituximab",
        "description": "Samsung Biologics and TG Therapeutics expand collaboration on ublituximab",
        "link": "https://www.thepharmaletter.com/article/samsung-biologics-and-tg-therapeutics-expand-collaboration-on-ublituximab",
        "pubDate": "2021-04-27 10:09:00"
    },
    {
        "filename": "pfizer-and-astrazeneca-see-overall-reputations-rise-in-survey.json",
        "title": "Pfizer and AstraZeneca see overall reputations rise in survey",
        "description": "The annual Corporate Reputation of Pharma survey for 2020 is unique in that the patient groups responding have the chance to comment on the industry\u00e2\u0080\u0099s performan",
        "link": "https://www.thepharmaletter.com/article/pfizer-and-astrazeneca-see-overall-reputations-rise-in-survey",
        "pubDate": "2021-04-27 02:00:00"
    },
    {
        "filename": "icer-ponders-options-for-strengthening-fda-s-aap.json",
        "title": "ICER ponders options for strengthening FDA\u00e2\u0080\u0099s AAP",
        "description": "US non-profit the Institute for Clinical and Economic Review (ICER), in collaboration with researchers from the Drug Pricing Lab at Memorial Sloan Kettering Can",
        "link": "https://www.thepharmaletter.com/article/icer-ponders-options-for-strengthening-fda-s-aap",
        "pubDate": "2021-04-26 18:05:00"
    },
    {
        "filename": "publish-lobbying-messages-from-pharma-uk-pm-told.json",
        "title": "Publish lobbying messages from pharma, UK PM told",
        "description": "A cross-party group of members of parliament (MPs) and peers in the UK have signed a joint statement with patient advocacy organizations calling for Prime Minis",
        "link": "https://www.thepharmaletter.com/article/publish-lobbying-messages-from-pharma-uk-pm-told",
        "pubDate": "2021-04-26 16:44:00"
    },
    {
        "filename": "former-fda-official-slams-agency-s-guidance-on-drug-reviews-during-covid-19-pandemic.json",
        "title": "Former FDA official criticizes agency's guidance on drug reviews during COVID-19 pandemic",
        "description": "Former FDA official slams agency's guidance on drug reviews during COVID-19 pandemic",
        "link": "https://www.thepharmaletter.com/article/former-fda-official-slams-agency-s-guidance-on-drug-reviews-during-covid-19-pandemic",
        "pubDate": "2021-04-26 16:33:00"
    },
    {
        "filename": "gsk-s-jemperli-becomes-first-anti-pd-1-therapy-oked-for-endometrial-cancer-in-eu.json",
        "title": "GSK\u00e2\u0080\u0099s Jemperli becomes first anti-PD-1 therapy OKed for endometrial cancer in EU",
        "description": "GSK\u00e2\u0080\u0099s Jemperli becomes first anti-PD-1 therapy OKed for endometrial cancer in EU",
        "link": "https://www.thepharmaletter.com/article/gsk-s-jemperli-becomes-first-anti-pd-1-therapy-oked-for-endometrial-cancer-in-eu",
        "pubDate": "2021-04-26 16:12:00"
    },
    {
        "filename": "ryvu-therapeutics-appoints-vatnak-vat-ho-as-cbo.json",
        "title": "Ryvu Therapeutics appoints Vatnak Vat-Ho as CBO",
        "description": "Ryvu Therapeutics appoints Vatnak Vat-Ho as CBO",
        "link": "https://www.thepharmaletter.com/article/ryvu-therapeutics-appoints-vatnak-vat-ho-as-cbo",
        "pubDate": "2021-04-26 15:30:00"
    },
    {
        "filename": "canada-starts-rolling-review-of-medicago-and-gsk-covid-19-vaccine.json",
        "title": "Canada starts rolling review of Medicago and GSK COVID-19 vaccine",
        "description": "Health Canada has begun the review of the rolling submission for Medicago\u00e2\u0080\u0099s plant-derived COVID-19 vaccine candidate in combination with GlaxoSmithKline\u00e2\u0080\u0099s pande",
        "link": "https://www.thepharmaletter.com/article/canada-starts-rolling-review-of-medicago-and-gsk-covid-19-vaccine",
        "pubDate": "2021-04-26 14:51:00"
    },
    {
        "filename": "pieris-out-licenses-prs-342-doe-up-to-365-million.json",
        "title": "Pieris out-licenses PRS-342 for up to $365 million",
        "description": "Pieris out-licenses PRS-342 doe up to $365 million",
        "link": "https://www.thepharmaletter.com/article/pieris-out-licenses-prs-342-doe-up-to-365-million",
        "pubDate": "2021-04-26 14:43:00"
    },
    {
        "filename": "fda-lifts-hold-on-uniqure-hemophilia-b-gene-therapy-program.json",
        "title": "FDA lifts hold on uniQure hemophilia B gene therapy program",
        "description": "FDA lifts hold on uniQure hemophilia B gene therapy program",
        "link": "https://www.thepharmaletter.com/article/fda-lifts-hold-on-uniqure-hemophilia-b-gene-therapy-program",
        "pubDate": "2021-04-26 13:55:00"
    },
    {
        "filename": "oxford-scientists-detail-real-world-impact-of-coronavirus-vaccination.json",
        "title": "Oxford scientists detail real-world impact of coronavirus vaccination",
        "description": "Large-scale research undertaken by the University of Oxford, published as two pre-prints, shows a significant fall in COVID-19 infections after a single vaccine",
        "link": "https://www.thepharmaletter.com/article/oxford-scientists-detail-real-world-impact-of-coronavirus-vaccination",
        "pubDate": "2021-04-26 13:28:00"
    },
    {
        "filename": "inovio-tanks-as-govt-funding-for-covid-19-vaccine-withdrawn.json",
        "title": "Inovio tanks as govt funding for COVID-19 vaccine withdrawn",
        "description": "Inovio tanks as govt funding for COVID-19 vaccine withdrawn",
        "link": "https://www.thepharmaletter.com/article/inovio-tanks-as-govt-funding-for-covid-19-vaccine-withdrawn",
        "pubDate": "2021-04-26 12:04:00"
    },
    {
        "filename": "nirsevimab-shows-positive-protective-profile-in-rsv.json",
        "title": "Nirsevimab shows positive protective profile in RSV",
        "description": "Nirsevimab shows positive protective profile in RSV",
        "link": "https://www.thepharmaletter.com/article/nirsevimab-shows-positive-protective-profile-in-rsv",
        "pubDate": "2021-04-26 10:56:00"
    },
    {
        "filename": "novartis-full-court-press-key-to-ensuring-rapid-zolgensma-access.json",
        "title": "Novartis\u00e2\u0080\u0099 \u00e2\u0080\u0098full-court press\u00e2\u0080\u0099 key to ensuring rapid Zolgensma access",
        "description": NaN,
        "link": "https://www.thepharmaletter.com/article/novartis-full-court-press-key-to-ensuring-rapid-zolgensma-access",
        "pubDate": "2021-04-26 10:22:00"
    },
    {
        "filename": "european-seal-of-approval-for-glenmark-s-innovation-strategy.json",
        "title": "European seal of approval for Glenmark's innovation strategy",
        "description": "Famous as a leading Indian maker of generics, Glenmark Pharmaceuticals has taken a major step towards boosting its credentials in the innovative medicine space,",
        "link": "https://www.thepharmaletter.com/article/european-seal-of-approval-for-glenmark-s-innovation-strategy",
        "pubDate": "2021-04-26 10:15:00"
    },
    {
        "filename": "hungary-s-health-ministry-on-sputnik-v-s-twitter-account.json",
        "title": "Hungary\u00e2\u0080\u0099s Health Ministry on Sputnik V\u00e2\u0080\u0099s Twitter account",
        "description": "Hungary\u00e2\u0080\u0099s Health Ministry on Sputnik V\u00e2\u0080\u0099s Twitter account",
        "link": "https://www.thepharmaletter.com/article/hungary-s-health-ministry-on-sputnik-v-s-twitter-account",
        "pubDate": "2021-04-26 10:10:00"
    },
    {
        "filename": "look-back-at-pharma-news-in-the-week-to-april-23-2021.json",
        "title": "Look back at pharma news in the week to April 23, 2021",
        "description": "Look back at pharma news in the week to April 23, 2021",
        "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-april-23-2021",
        "pubDate": "2021-04-25 11:15:00"
    },
    {
        "filename": "adc-therapeutics-zynlonta-gains-us-approval-for-r-r-dlbcl.json",
        "title": "ADC Therapeutics\u00e2\u0080\u0099 Zynlonta gains US approval for r/r DLBCL",
        "description": "ADC Therapeutics\u00e2\u0080\u0099 Zynlonta gains US approval for r/r DLBCL",
        "link": "https://www.thepharmaletter.com/article/adc-therapeutics-zynlonta-gains-us-approval-for-r-r-dlbcl",
        "pubDate": "2021-04-24 15:45:00"
    },
    {
        "filename": "increase-in-production-capacity-for-covid-19-vaccines-in-eu.json",
        "title": "Increase in production capacity for COVID-19 vaccines in EU",
        "description": "Increase in production capacity for COVID-19 vaccines in EU",
        "link": "https://www.thepharmaletter.com/article/increase-in-production-capacity-for-covid-19-vaccines-in-eu",
        "pubDate": "2021-04-24 14:54:00"
    },
    {
        "filename": "boehringer-says-data-supports-interchangeability-of-cyltezo-with-humira.json",
        "title": "Boehringer says data supports interchangeability of Cyltezo with Humira",
        "description": "Boehringer says data supports interchangeability of Cyltezo with Humira",
        "link": "https://www.thepharmaletter.com/article/boehringer-says-data-supports-interchangeability-of-cyltezo-with-humira",
        "pubDate": "2021-04-24 14:29:00"
    },
    {
        "filename": "zydus-covid-19-drug-gets-eua-from-indian-regulator-as-cases-spiral.json",
        "title": "Zydus COVID-19 drug gets EUA from Indian regulator as cases spiral",
        "description": "Indian drugmaker Zydus Cadila has received restricted emergency use approval (EUA) from the Drug Controller General of India (DCGI) for the use of Virafin (pegy",
        "link": "https://www.thepharmaletter.com/article/zydus-covid-19-drug-gets-eua-from-indian-regulator-as-cases-spiral",
        "pubDate": "2021-04-23 18:05:00"
    },
    {
        "filename": "new-medicines-recommended-for-approval-by-ema-s-chmp.json",
        "title": "New medicines recommended for approval by EMA\u00e2\u0080\u0099s CHMP",
        "description": "New medicines recommended for approval by EMA\u00e2\u0080\u0099s CHMP",
        "link": "https://www.thepharmaletter.com/article/new-medicines-recommended-for-approval-by-ema-s-chmp",
        "pubDate": "2021-04-23 16:24:00"
    },
    {
        "filename": "lonza-investing-200-million-francs-in-new-manufacturing-complex.json",
        "title": "Lonza investing 200 million francs in new manufacturing complex",
        "description": "Lonza investing 200 million francs in new manufacturing complex",
        "link": "https://www.thepharmaletter.com/article/lonza-investing-200-million-francs-in-new-manufacturing-complex",
        "pubDate": "2021-04-23 14:42:00"
    },
    {
        "filename": "vertex-inks-licensing-deal-with-obsidian.json",
        "title": "Vertex inks licensing deal with Obsidian",
        "description": "Vertex inks licensing deal with Obsidian",
        "link": "https://www.thepharmaletter.com/article/vertex-inks-licensing-deal-with-obsidian",
        "pubDate": "2021-04-23 14:15:00"
    },
    {
        "filename": "europe-threatens-legal-action-over-astrazeneca-vaccine-supplies.json",
        "title": "Europe threatens legal action over AstraZeneca vaccine supplies",
        "description": "The latest chapter in an ongoing saga over European supplies of AstraZeneca\u00e2\u0080\u0099s coronavirus vaccine looks like to involve legal action.",
        "link": "https://www.thepharmaletter.com/article/europe-threatens-legal-action-over-astrazeneca-vaccine-supplies",
        "pubDate": "2021-04-23 11:42:00"
    },
    {
        "filename": "new-long-term-data-for-uplinza.json",
        "title": "New long-term data for Uplinza",
        "description": "New long-term data for Uplinza",
        "link": "https://www.thepharmaletter.com/article/new-long-term-data-for-uplinza",
        "pubDate": "2021-04-23 10:59:00"
    },
    {
        "filename": "gsk-targets-endometrial-cancer-with-fda-approved-checkpoint-blocker.json",
        "title": "GSK targets endometrial cancer with FDA-approved checkpoint blocker",
        "description": "The US Food and Drug Administration has approved Jemperli (dostarlimab-gxly), a checkpoint blocker developed by UK drugmaker GlaxoSmithKline.",
        "link": "https://www.thepharmaletter.com/article/gsk-targets-endometrial-cancer-with-fda-approved-checkpoint-blocker",
        "pubDate": "2021-04-23 10:29:00"
    },
    {
        "filename": "mhra-green-lights-new-treatment-to-reduce-the-risk-of-cardiovascular-events.json",
        "title": "MHRA green lights new treatment to reduce the risk of cardiovascular events",
        "description": "MHRA green lights new treatment to reduce the risk of cardiovascular events",
        "link": "https://www.thepharmaletter.com/article/mhra-green-lights-new-treatment-to-reduce-the-risk-of-cardiovascular-events",
        "pubDate": "2021-04-23 00:00:00"
    },
    {
        "filename": "jazz-presents-positive-xywav-data-at-aan-2021.json",
        "title": "Jazz presents positive Xywav data at AAN 2021",
        "description": "Ireland-headquartered Jazz Pharmaceuticals has announced positive results from a Phase III study of Xywav (calcium, magnesium, potassium, and sodium oxybates).",
        "link": "https://www.thepharmaletter.com/article/jazz-presents-positive-xywav-data-at-aan-2021",
        "pubDate": "2021-04-22 16:54:00"
    },
    {
        "filename": "biogen-beats-expectations-despite-24-sales-dive.json",
        "title": "Biogen beats expectations, despite 24% sales dive",
        "description": "Biogen beats expectations, despite 24% sales dive",
        "link": "https://www.thepharmaletter.com/article/biogen-beats-expectations-despite-24-sales-dive",
        "pubDate": "2021-04-22 16:19:00"
    },
    {
        "filename": "bms-to-build-new-cell-therapy-manufacturing-site-in-europe.json",
        "title": "BMS to build new cell therapy manufacturing site in Europe",
        "description": "BMS to build new cell therapy manufacturing site in Europe",
        "link": "https://www.thepharmaletter.com/article/bms-to-build-new-cell-therapy-manufacturing-site-in-europe",
        "pubDate": "2021-04-22 14:22:00"
    },
    {
        "filename": "cphi-covid-19-driving-manufacturing-and-cdmos-driving-growth.json",
        "title": "CPhI: COVID-19 driving manufacturing and CDMOs driving growth",
        "description": "CPhI: COVID-19 driving manufacturing and CDMOs driving growth",
        "link": "https://www.thepharmaletter.com/article/cphi-covid-19-driving-manufacturing-and-cdmos-driving-growth",
        "pubDate": "2021-04-22 14:04:00"
    },
    {
        "filename": "latin-american-countries-fight-antimicrobial-resistance.json",
        "title": "Latin American countries fight antimicrobial resistance",
        "description": "Argentina, Brazil, Chile, Colombia, Paraguay, Peru and Uruguay are the seven Latin American countries selected to receive support from the European Union (EU) t",
        "link": "https://www.thepharmaletter.com/article/latin-american-countries-fight-antimicrobial-resistance",
        "pubDate": "2021-04-22 13:43:00"
    },
    {
        "filename": "vaccine-companies-shareholders-profits-would-pay-to-vaccinate-africa-say-campaigners.json",
        "title": "Vaccine companies shareholders\u00e2\u0080\u0099 profits would pay to vaccinate Africa, say campaigners",
        "description": NaN,
        "link": "https://www.thepharmaletter.com/article/vaccine-companies-shareholders-profits-would-pay-to-vaccinate-africa-say-campaigners",
        "pubDate": "2021-04-22 12:58:00"
    },
    {
        "filename": "anavo-therapeutics-launches-with-20-million-euros-seed-financing.json",
        "title": "Anavo Therapeutics launches with 20 million euros seed financing",
        "description": "Anavo Therapeutics launches with 20 million euros seed financing",
        "link": "https://www.thepharmaletter.com/article/anavo-therapeutics-launches-with-20-million-euros-seed-financing",
        "pubDate": "2021-04-22 12:04:00"
    },
    {
        "filename": "phase-iii-trial-could-pave-way-for-new-covid-19-vaccine-in-the-uk.json",
        "title": "Phase III trial could pave way for new COVID-19 vaccine in the UK",
        "description": "French vaccine specialist Valneva (EPA: VLA) has kicked off a Phase III trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.",
        "link": "https://www.thepharmaletter.com/article/phase-iii-trial-could-pave-way-for-new-covid-19-vaccine-in-the-uk",
        "pubDate": "2021-04-22 11:34:00"
    },
    {
        "filename": "us-patents-for-nicox-vyzulta-eligible-for-term-extension.json",
        "title": "US patents for Nicox\u00e2\u0080\u0099 Vyzulta eligible for term extension",
        "description": "US patents for Nicox\u00e2\u0080\u0099 Vyzulta eligible for term extension",
        "link": "https://www.thepharmaletter.com/article/us-patents-for-nicox-vyzulta-eligible-for-term-extension",
        "pubDate": "2021-04-22 10:48:00"
    },
    {
        "filename": "pureos-bioventures-expands-fund-to-205-million.json",
        "title": "Pureos Bioventures expands fund to $205 million",
        "description": "Pureos Bioventures expands fund to $205 million",
        "link": "https://www.thepharmaletter.com/article/pureos-bioventures-expands-fund-to-205-million",
        "pubDate": "2021-04-22 10:26:00"
    },
    {
        "filename": "eu-commission-and-austria-secure-covid-19-vaccines-for-the-western-balkans.json",
        "title": "EU Commission and Austria secure COVID-19 vaccines for the Western Balkans",
        "description": "EU Commission and Austria secure COVID-19 vaccines for the Western Balkans",
        "link": "https://www.thepharmaletter.com/article/eu-commission-and-austria-secure-covid-19-vaccines-for-the-western-balkans",
        "pubDate": "2021-04-21 16:51:00"
    },
    {
        "filename": "cancer-cachexia-drug-adlumiz-launched-in-japan.json",
        "title": "Cancer cachexia drug Adlumiz launched in Japan",
        "description": "Privately-owned Swiss drugmaker Helsinn has announced the launch of Adlumiz (anamorelin) for the treatment of cancer cachexia in malignant non-small cell lung c",
        "link": "https://www.thepharmaletter.com/article/cancer-cachexia-drug-adlumiz-launched-in-japan",
        "pubDate": "2021-04-21 16:31:00"
    },
    {
        "filename": "diurnal-completes-20-million-placing-to-fund-us-phase-iii-clinical-trial.json",
        "title": "Diurnal completes \u00c2\u00a320 million placing to fund US Phase III clinical trial",
        "description": "Diurnal completes \u00c2\u00a320 million placing to fund US Phase III clinical trial",
        "link": "https://www.thepharmaletter.com/article/diurnal-completes-20-million-placing-to-fund-us-phase-iii-clinical-trial",
        "pubDate": "2021-04-21 16:22:00"
    },
    {
        "filename": "hikma-resumes-launch-of-generic-advair-diskus-in-usa.json",
        "title": "Hikma resumes launch of generic Advair Diskus in USA",
        "description": "Hikma resumes launch of generic Advair Diskus in USA",
        "link": "https://www.thepharmaletter.com/article/hikma-resumes-launch-of-generic-advair-diskus-in-usa",
        "pubDate": "2021-04-21 14:12:00"
    },
    {
        "filename": "roche-1st-qrt-sales-hit-by-pandemic-and-biosimilars-competition.json",
        "title": "Roche 1st-qrt sales hit by pandemic and biosimilars competition",
        "description": "Roche 1st-qrt sales hit by pandemic and biosimilars competition",
        "link": "https://www.thepharmaletter.com/article/roche-1st-qrt-sales-hit-by-pandemic-and-biosimilars-competition",
        "pubDate": "2021-04-21 12:27:00"
    },
    {
        "filename": "generating-the-right-evidence-to-support-your-brand-s-value-story-does-your-team-have-all-the-pieces-of-the-puzzle.json",
        "title": "Generating the right evidence to support your brand\u00e2\u0080\u0099s value story - does your team have all the pieces of the puzzle?",
        "description": "Nicola Mahy, director at Align Strategy, makes the case for an integrated evidence plan to maximize patient access to a brand in an Expert View piece.",
        "link": "https://www.thepharmaletter.com/article/generating-the-right-evidence-to-support-your-brand-s-value-story-does-your-team-have-all-the-pieces-of-the-puzzle",
        "pubDate": "2021-04-21 12:15:00"
    },
    {
        "filename": "vertex-and-crispr-therapeutics-amend-deal-on-ctx001-gene-therapy.json",
        "title": "Vertex and CRISPR Therapeutics amend deal on CTX001 gene therapy",
        "description": "Vertex and CRISPR Therapeutics amend deal on CTX001 gene therapy",
        "link": "https://www.thepharmaletter.com/article/vertex-and-crispr-therapeutics-amend-deal-on-ctx001-gene-therapy",
        "pubDate": "2021-04-21 11:05:00"
    },
    {
        "filename": "nasal-spray-works-against-covid-19-variants.json",
        "title": "Nasal spray works against COVID-19 variants",
        "description": "A nasal spray designed to block the novel coronavirus, from Austrian drug developer Marinomed Biotech, has been shown to inactivate new, rapidly spreading varia",
        "link": "https://www.thepharmaletter.com/article/nasal-spray-works-against-covid-19-variants",
        "pubDate": "2021-04-21 10:30:00"
    },
    {
        "filename": "sputnik-v-production-launched-in-argentina.json",
        "title": "Sputnik V production launched in Argentina",
        "description": "Sputnik V production launched in Argentina",
        "link": "https://www.thepharmaletter.com/article/sputnik-v-production-launched-in-argentina",
        "pubDate": "2021-04-21 10:29:00"
    },
    {
        "filename": "issar-pharma-out-licenses-peptide-based-nces.json",
        "title": "Issar Pharma out-licenses peptide-based NCEs",
        "description": "Issar Pharma out-licenses peptide-based NCEs",
        "link": "https://www.thepharmaletter.com/article/issar-pharma-out-licenses-peptide-based-nces",
        "pubDate": "2021-04-21 10:12:00"
    },
    {
        "filename": "bluebird-bio-updates-on-genetic-disease-portfolio.json",
        "title": "bluebird bio updates on genetic disease portfolio",
        "description": "bluebird bio updates on genetic disease portfolio",
        "link": "https://www.thepharmaletter.com/article/bluebird-bio-updates-on-genetic-disease-portfolio",
        "pubDate": "2021-04-20 17:09:00"
    },
    {
        "filename": "add-blood-clot-risk-to-j-j-jab-product-info-says-ema.json",
        "title": "Add blood clot risk to J&J jab product info, says EMA",
        "description": "At its meeting on Tuesday, the European Medicines Agency\u00e2\u0080\u0099s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) decided that a warning about unusual blood c",
        "link": "https://www.thepharmaletter.com/article/add-blood-clot-risk-to-j-j-jab-product-info-says-ema",
        "pubDate": "2021-04-20 16:33:00"
    },
    {
        "filename": "baricitinib-improved-hair-regrowth-for-alopecia-patients-in-phase-iii-study.json",
        "title": "Baricitinib improved hair regrowth for alopecia patients in Phase III study",
        "description": "Baricitinib improved hair regrowth for alopecia patients in Phase III study",
        "link": "https://www.thepharmaletter.com/article/baricitinib-improved-hair-regrowth-for-alopecia-patients-in-phase-iii-study",
        "pubDate": "2021-04-20 16:21:00"
    },
    {
        "filename": "fda-accepts-two-priority-review-sblas-for-padcev.json",
        "title": "FDA accepts two priority review sBLAs for Padcev",
        "description": "FDA accepts two priority review sBLAs for Padcev",
        "link": "https://www.thepharmaletter.com/article/fda-accepts-two-priority-review-sblas-for-padcev",
        "pubDate": "2021-04-20 15:43:00"
    },
    {
        "filename": "evotec-ups-investment-in-biologic-manufacturing-facility-in-toulouse.json",
        "title": "Evotec ups investment in biologic manufacturing facility in Toulouse",
        "description": "Evotec ups investment in biologic manufacturing facility in Toulouse",
        "link": "https://www.thepharmaletter.com/article/evotec-ups-investment-in-biologic-manufacturing-facility-in-toulouse",
        "pubDate": "2021-04-20 14:48:00"
    },
    {
        "filename": "sparingvision-expands-ocular-disease-pipeline-with-buy-of-gamut-therapeutics.json",
        "title": "SparingVision expands ocular disease pipeline with buy of GAMUT Therapeutics",
        "description": "SparingVision expands ocular disease pipeline with buy of GAMUT Therapeutics",
        "link": "https://www.thepharmaletter.com/article/sparingvision-expands-ocular-disease-pipeline-with-buy-of-gamut-therapeutics",
        "pubDate": "2021-04-20 13:42:00"
    },
    {
        "filename": "j-j-results-show-significant-growth-in-sales-and-earnings.json",
        "title": "J&J results show significant growth in sales and earnings",
        "description": "US healthcare giant Johnson & Johnson has announced results for the first quarter of 2021.",
        "link": "https://www.thepharmaletter.com/article/j-j-results-show-significant-growth-in-sales-and-earnings",
        "pubDate": "2021-04-20 13:24:00"
    },
    {
        "filename": "encouraging-phase-ii-data-for-alzheimer-s-candidate-ban2401.json",
        "title": "Encouraging Phase II data for Alzheimer's candidate BAN2401",
        "description": "Japanese drugmaker Eisai, one of an increasingly small number of major players still working in the Alzheimer\u00e2\u0080\u0099s space, has published results from a Phase IIb tr",
        "link": "https://www.thepharmaletter.com/article/encouraging-phase-ii-data-for-alzheimer-s-candidate-ban2401",
        "pubDate": "2021-04-20 12:53:00"
    },
    {
        "filename": "enhertu-recommended-for-cdf-inclusion-in-england.json",
        "title": "Enhertu recommended for CDF inclusion in England",
        "description": "The National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) to trea",
        "link": "https://www.thepharmaletter.com/article/enhertu-recommended-for-cdf-inclusion-in-england",
        "pubDate": "2021-04-20 11:57:00"
    },
    {
        "filename": "helios-a-phase-iii-study-of-vutrisiran-meets-goals.json",
        "title": "HELIOS-A Phase III study of vutrisiran meets goals",
        "description": "HELIOS-A Phase III study of vutrisiran meets goals",
        "link": "https://www.thepharmaletter.com/article/helios-a-phase-iii-study-of-vutrisiran-meets-goals",
        "pubDate": "2021-04-20 11:54:00"
    },
    {
        "filename": "us-fda-places-clinical-trial-hold-on-anixa-s-novel-car-t-cell-therapy.json",
        "title": "US FDA pauses work on Anixa's novel CAR-T cell candidate",
        "description": "Anixa Biosciences has been subjected to a clinical trial hold for a CAR-T cell therapy being developed in partnership with Moffitt Cancer Center (MCC).",
        "link": "https://www.thepharmaletter.com/article/us-fda-places-clinical-trial-hold-on-anixa-s-novel-car-t-cell-therapy",
        "pubDate": "2021-04-20 11:06:00"
    },
    {
        "filename": "i-o-will-be-dominant-drug-class-for-liver-cancer-by-2029-says-analyst.json",
        "title": "I-O will be dominant drug class for liver cancer by 2029, says analyst",
        "description": "I-O will be dominant drug class for liver cancer by 2029, says analyst",
        "link": "https://www.thepharmaletter.com/article/i-o-will-be-dominant-drug-class-for-liver-cancer-by-2029-says-analyst",
        "pubDate": "2021-04-20 10:53:00"
    },
    {
        "filename": "russian-pharma-production-booming-anticipating-third-wave-of-pandemic.json",
        "title": "Russian pharma production booming, anticipating third wave of pandemic",
        "description": "Russian pharma production booming, anticipating third wave of pandemic",
        "link": "https://www.thepharmaletter.com/article/russian-pharma-production-booming-anticipating-third-wave-of-pandemic",
        "pubDate": "2021-04-20 10:51:00"
    },
    {
        "filename": "more-manufacturing-woes-add-to-j-j-s-vaccine-worries.json",
        "title": "More manufacturing woes add to J&J's vaccine worries",
        "description": NaN,
        "link": "https://www.thepharmaletter.com/article/more-manufacturing-woes-add-to-j-j-s-vaccine-worries",
        "pubDate": "2021-04-20 10:13:00"
    },
    {
        "filename": "sputnik-v-labelled-most-efficient-covid-19-vaccine-as-china-manufacturing-deal-announced.json",
        "title": "Sputnik V labelled \u00e2\u0080\u0098most efficient COVID-19 vaccine\u00e2\u0080\u0099 as China manufacturing deal announced",
        "description": "Whether Russia\u00e2\u0080\u0099s Sputnik V is the world\u00e2\u0080\u0099s most effective COVID-19 vaccine remains uncertain in a constantly-evolving landscape, but it can probably claim to hav",
        "link": "https://www.thepharmaletter.com/article/sputnik-v-labelled-most-efficient-covid-19-vaccine-as-china-manufacturing-deal-announced",
        "pubDate": "2021-04-19 17:16:00"
    },
    {
        "filename": "carb-x-funds-phico-to-develop-new-intravenous-engineered-bacteriophage-drug.json",
        "title": "CARB-X funds Phico to develop new intravenous engineered bacteriophage drug",
        "description": "Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat",
        "link": "https://www.thepharmaletter.com/article/carb-x-funds-phico-to-develop-new-intravenous-engineered-bacteriophage-drug",
        "pubDate": "2021-04-19 15:51:00"
    },
    {
        "filename": "india-s-sii-appeals-to-us-president-against-ingredient-export-ban.json",
        "title": "India\u00e2\u0080\u0099s SII appeals to US President against ingredient export ban",
        "description": "India\u00e2\u0080\u0099s SII appeals to US President against ingredient export ban",
        "link": "https://www.thepharmaletter.com/article/india-s-sii-appeals-to-us-president-against-ingredient-export-ban",
        "pubDate": "2021-04-19 13:57:00"
    },
    {
        "filename": "deal-for-further-100-million-doses-of-pfizer-and-biontech-jab-to-go-to-eu.json",
        "title": "Deal for further 100 million doses of Pfizer and BioNTech jab to go to EU",
        "description": "Pfizer and BioNTech are to supply an additional 100 million doses of Comirnaty, the companies\u00e2\u0080\u0099 COVID-19 vaccine, to the 27 European Union (EU) member states in ",
        "link": "https://www.thepharmaletter.com/article/deal-for-further-100-million-doses-of-pfizer-and-biontech-jab-to-go-to-eu",
        "pubDate": "2021-04-19 13:37:00"
    },
    {
        "filename": "biogen-advances-research-in-sma-with-new-data-at-aan-2021.json",
        "title": "Biogen advances research in SMA, with new data at AAN 2021",
        "description": "Biogen advances research in SMA, with new data at AAN 2021",
        "link": "https://www.thepharmaletter.com/article/biogen-advances-research-in-sma-with-new-data-at-aan-2021",
        "pubDate": "2021-04-19 13:00:00"
    },
    {
        "filename": "adagio-thera-nabs-336-million-financing-to-progress-adg20-antibody.json",
        "title": "Adagio Thera nabs $336 million financing to progress ADG20 antibody",
        "description": "Adagio Thera nabs $336 million financing to progress ADG20 antibody",
        "link": "https://www.thepharmaletter.com/article/adagio-thera-nabs-336-million-financing-to-progress-adg20-antibody",
        "pubDate": "2021-04-19 12:23:00"
    },
    {
        "filename": "highly-selective-cancer-drug-in-360-million-development-deal.json",
        "title": "Highly selective cancer drug in $360 million development deal",
        "description": "Hamburg\u00e2\u0080\u0099s Evotec has entered into both a licensing and master service agreement with Australian oncology-focussed biotech Kazia Therapeutics.",
        "link": "https://www.thepharmaletter.com/article/highly-selective-cancer-drug-in-360-million-development-deal",
        "pubDate": "2021-04-19 12:06:00"
    },
    {
        "filename": "alk-gains-us-pediatric-approval-for-its-ragweed-slit-tablet.json",
        "title": "ALK gains US pediatric approval for its ragweed SLIT-tablet",
        "description": "ALK gains US pediatric approval for its ragweed SLIT-tablet",
        "link": "https://www.thepharmaletter.com/article/alk-gains-us-pediatric-approval-for-its-ragweed-slit-tablet",
        "pubDate": "2021-04-19 11:50:00"
    },
    {
        "filename": "on-vaccine-side-effects-big-pharma-s-not-all-in-it-together.json",
        "title": "On vaccine side effects, big pharma's not all in it together",
        "description": "Johnson & Johnson reportedly reached out to fellow vaccine developers to work together on evaluating possible vaccine-linked blood clotting events, but was rebu",
        "link": "https://www.thepharmaletter.com/article/on-vaccine-side-effects-big-pharma-s-not-all-in-it-together",
        "pubDate": "2021-04-19 11:21:00"
    },
    {
        "filename": "second-indication-of-sarclisa-for-relapsed-mm-approved-by-ec.json",
        "title": "Second indication of Sarclisa for relapsed MM approved by EC",
        "description": "Second indication of Sarclisa for relapsed MM approved by EC",
        "link": "https://www.thepharmaletter.com/article/second-indication-of-sarclisa-for-relapsed-mm-approved-by-ec",
        "pubDate": "2021-04-19 10:46:00"
    },
    {
        "filename": "russia-s-aipm-et-al-warn-of-dangers-of-a-second-extra.json",
        "title": "Russia\u00e2\u0080\u0099s AIPM et al warn of dangers of a \u00e2\u0080\u009csecond extra\u00e2\u0080\u009d",
        "description": "Russia\u00e2\u0080\u0099s AIPM et al warn of dangers of a \u00e2\u0080\u009csecond extra\u00e2\u0080\u009d",
        "link": "https://www.thepharmaletter.com/article/russia-s-aipm-et-al-warn-of-dangers-of-a-second-extra",
        "pubDate": "2021-04-19 10:12:00"
    },
    {
        "filename": "amgen-s-bet-on-five-prime-needs-more-than-one-label-for-bemarituzumab-to-pay-off-says-analyst.json",
        "title": "Amgen\u00e2\u0080\u0099s bet on Five Prime needs more than one label for bemarituzumab to pay off, says analyst",
        "description": "Amgen\u00e2\u0080\u0099s bet on Five Prime needs more than one label for bemarituzumab to pay off, says analyst",
        "link": "https://www.thepharmaletter.com/article/amgen-s-bet-on-five-prime-needs-more-than-one-label-for-bemarituzumab-to-pay-off-says-analyst",
        "pubDate": "2021-04-19 10:11:00"
    },
    {
        "filename": "look-back-at-pharma-news-in-the-week-to-april-16-2021.json",
        "title": "Look back at pharma news in the week to April 16, 2021",
        "description": "Look back at pharma news in the week to April 16, 2021",
        "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-april-16-2021",
        "pubDate": "2021-04-18 10:38:00"
    },
    {
        "filename": "fda-green-lights-first-immunotherapy-as-initial-gastric-cancer-therapy.json",
        "title": "FDA green lights first immunotherapy as initial gastric cancer therapy",
        "description": "FDA green lights first immunotherapy as initial gastric cancer therapy",
        "link": "https://www.thepharmaletter.com/article/fda-green-lights-first-immunotherapy-as-initial-gastric-cancer-therapy",
        "pubDate": "2021-04-17 14:19:00"
    },
    {
        "filename": "fda-revokes-eua-for-mab-bamlanivimab-for-covid-19.json",
        "title": "FDA revokes EUA for MAb bamlanivimab for COVID-19",
        "description": "FDA revokes EUA for MAb bamlanivimab for COVID-19",
        "link": "https://www.thepharmaletter.com/article/fda-revokes-eua-for-mab-bamlanivimab-for-covid-19",
        "pubDate": "2021-04-17 13:21:00"
    },
    {
        "filename": "final-icer-evidence-report-on-lupus-nephritis-drugs.json",
        "title": "Final ICER evidence report on Lupus nephritis drugs",
        "description": "Final ICER evidence report on Lupus nephritis drugs",
        "link": "https://www.thepharmaletter.com/article/final-icer-evidence-report-on-lupus-nephritis-drugs",
        "pubDate": "2021-04-16 14:01:00"
    },
    {
        "filename": "new-data-attest-to-benefits-of-kesimpta-in-ms.json",
        "title": "New data attest to benefits of Kesimpta in MS",
        "description": "Swiss pharma giant Novartis has announced new post hoc data from the Phase III ASCLEPIOS trials of Kesimpta (ofatumumab).",
        "link": "https://www.thepharmaletter.com/article/new-data-attest-to-benefits-of-kesimpta-in-ms",
        "pubDate": "2021-04-16 13:21:00"
    },
    {
        "filename": "support-the-scrapping-of-patents-to-avoid-undermining-vaccination-drive-uk-government-told.json",
        "title": "Support the scrapping of patents to avoid undermining vaccination drive, UK government told",
        "description": "The government must support a patent waiver for COVID-19 vaccines and treatments to protect the UK\u00e2\u0080\u0099s own vaccination program, according to public health experts",
        "link": "https://www.thepharmaletter.com/article/support-the-scrapping-of-patents-to-avoid-undermining-vaccination-drive-uk-government-told",
        "pubDate": "2021-04-16 12:41:00"
    },
    {
        "filename": "2021-inflection-point-for-genmab-says-chief-executive.json",
        "title": "2021 \"inflection point\" for Genmab, says chief executive",
        "description": "Danish company Genmab has a lot going on this year, as chief executive Jan van de Winkel tells The Pharma Letter.",
        "link": "https://www.thepharmaletter.com/article/2021-inflection-point-for-genmab-says-chief-executive",
        "pubDate": "2021-04-16 12:35:00"
    },
    {
        "filename": "strong-new-data-for-roche-s-ocrevus-in-ms.json",
        "title": "Strong new data for Roche\u00e2\u0080\u0099s Ocrevus in MS",
        "description": "Strong new data for Roche\u00e2\u0080\u0099s Ocrevus in MS",
        "link": "https://www.thepharmaletter.com/article/strong-new-data-for-roche-s-ocrevus-in-ms",
        "pubDate": "2021-04-16 12:26:00"
    },
    {
        "filename": "listening-to-patients-the-fda-goes-from-strength-to-strength.json",
        "title": "Listening to patients: The FDA goes from strength to strength",
        "description": "Listening to patients: The FDA goes from strength to strength",
        "link": "https://www.thepharmaletter.com/article/listening-to-patients-the-fda-goes-from-strength-to-strength",
        "pubDate": "2021-04-16 12:25:00"
    },
    {
        "filename": "novel-immuno-oncology-approach-shows-promise.json",
        "title": "Novel immuno-oncology approach shows promise",
        "description": "A licensing deal between XOMA Corporation and Affimed Therapeutics is starting to bear fruit, with progress in three innate cell engager (ICE) programs.",
        "link": "https://www.thepharmaletter.com/article/novel-immuno-oncology-approach-shows-promise",
        "pubDate": "2021-04-16 12:24:00"
    },
    {
        "filename": "ema-to-review-vir-7831-for-the-early-treatment-of-covid-19.json",
        "title": "EMA to review VIR-7831 for the early treatment of COVID-19",
        "description": "EMA to review VIR-7831 for the early treatment of COVID-19",
        "link": "https://www.thepharmaletter.com/article/ema-to-review-vir-7831-for-the-early-treatment-of-covid-19",
        "pubDate": "2021-04-16 12:23:00"
    },
    {
        "filename": "global-confidence-in-astrazeneca-s-covid-19-vaccine-could-be-boosted-by-fda-eua.json",
        "title": "Global confidence in AstraZeneca\u00e2\u0080\u0099s COVID-19 vaccine could be boosted by FDA EUA",
        "description": "Global confidence in AstraZeneca\u00e2\u0080\u0099s COVID-19 vaccine could be boosted by FDA EUA",
        "link": "https://www.thepharmaletter.com/article/global-confidence-in-astrazeneca-s-covid-19-vaccine-could-be-boosted-by-fda-eua",
        "pubDate": "2021-04-16 12:22:00"
    },
    {
        "filename": "xoma-the-royalty-aggregator-that-thinks-like-a-biotech.json",
        "title": "XOMA: The royalty aggregator that thinks like a biotech",
        "description": "For biotech companies, the prospect of receiving non-dilutive, non-recourse funding to advance their assets even through the early stages of clinical developmen",
        "link": "https://www.thepharmaletter.com/article/xoma-the-royalty-aggregator-that-thinks-like-a-biotech",
        "pubDate": "2021-04-16 12:11:00"
    },
    {
        "filename": "asthma-treatment-fails-phase-iii-test-in-covid-19.json",
        "title": "Asthma treatment fails Phase III test in COVID-19",
        "description": "Swiss pharmaceutical company Covis Pharma has announced negative top-line results from a 400 patient Phase III trial of ciclesonide in non-hospitalized people w",
        "link": "https://www.thepharmaletter.com/article/asthma-treatment-fails-phase-iii-test-in-covid-19",
        "pubDate": "2021-04-15 16:56:00"
    },
    {
        "filename": "bioage-signs-deal-with-amgen-to-develop-phase-i-apj-agonist.json",
        "title": "BioAge signs deal with Amgen to develop Phase I APJ agonist",
        "description": "BioAge signs deal with Amgen to develop Phase I APJ agonist",
        "link": "https://www.thepharmaletter.com/article/bioage-signs-deal-with-amgen-to-develop-phase-i-apj-agonist",
        "pubDate": "2021-04-15 16:34:00"
    },
    {
        "filename": "alchemab-raises-60-million-in-series-a-financing.json",
        "title": "Alchemab raises \u00c2\u00a360 million in Series A financing",
        "description": "Alchemab raises \u00c2\u00a360 million in Series A financing",
        "link": "https://www.thepharmaletter.com/article/alchemab-raises-60-million-in-series-a-financing",
        "pubDate": "2021-04-15 15:57:00"
    },
    {
        "filename": "nice-backs-ultomiris-for-adult-patients-with-pnh.json",
        "title": "NICE backs Ultomiris for adult patients with PNH",
        "description": "NICE backs Ultomiris for adult patients with PNH",
        "link": "https://www.thepharmaletter.com/article/nice-backs-ultomiris-for-adult-patients-with-pnh",
        "pubDate": "2021-04-15 15:16:00"
    },
    {
        "filename": "diurnal-withdraws-ema-orphan-designation-request-for-efmody-chronocort.json",
        "title": "Diurnal withdraws EMA orphan designation request for Efmody/Chronocort",
        "description": "UK endocrine diseases specialist Diurnal Group has withdrawn its application for maintenance of orphan designation in Europe for Efmody (hydrocortisone modified",
        "link": "https://www.thepharmaletter.com/article/diurnal-withdraws-ema-orphan-designation-request-for-efmody-chronocort",
        "pubDate": "2021-04-15 14:50:00"
    },
    {
        "filename": "merck-to-discontinue-mk-7110-for-covid-19-development.json",
        "title": "Merck to discontinue MK-7110 for COVID-19 development",
        "description": "Merck to discontinue MK-7110 for COVID-19 development",
        "link": "https://www.thepharmaletter.com/article/merck-to-discontinue-mk-7110-for-covid-19-development",
        "pubDate": "2021-04-15 14:32:00"
    },
    {
        "filename": "russia-seeks-to-distance-sputnik-v-from-blood-clotting-cases.json",
        "title": "Russia seeks to distance Sputnik V from blood clotting cases",
        "description": "The developers of Russia\u00e2\u0080\u0099s Sputnik V have sought to differentiate its option from other vaccines which may be linked to a rare side effect of blood clotting.",
        "link": "https://www.thepharmaletter.com/article/russia-seeks-to-distance-sputnik-v-from-blood-clotting-cases",
        "pubDate": "2021-04-15 12:55:00"
    },
    {
        "filename": "strong-evrysdi-data-keep-coming-in-sma.json",
        "title": "Strong Evrysdi data keep coming in SMA",
        "description": "PTC Therapeutics has announced new data showing continued improvements in motor milestones in infants with type 1 spinal muscular atrophy (SMA) after two years ",
        "link": "https://www.thepharmaletter.com/article/strong-evrysdi-data-keep-coming-in-sma",
        "pubDate": "2021-04-15 12:34:00"
    },
    {
        "filename": "abcellera-and-empirico-collaboration.json",
        "title": "AbCellera and Empirico collaboration",
        "description": "AbCellera and Empirico collaboration",
        "link": "https://www.thepharmaletter.com/article/abcellera-and-empirico-collaboration",
        "pubDate": "2021-04-15 12:22:00"
    },
    {
        "filename": "gsk-stops-phase-ii-feladilimab-trial.json",
        "title": "GSK stops Phase II feladilimab trial",
        "description": "GSK stops Phase II feladilimab trial",
        "link": "https://www.thepharmaletter.com/article/gsk-stops-phase-ii-feladilimab-trial",
        "pubDate": "2021-04-15 11:54:00"
    },
    {
        "filename": "scineuro-pharma-inks-antibody-licensing-deal-with-lilly.json",
        "title": "SciNeuro Pharma inks antibody licensing deal with Lilly",
        "description": "SciNeuro Pharma inks antibody licensing deal with Lilly",
        "link": "https://www.thepharmaletter.com/article/scineuro-pharma-inks-antibody-licensing-deal-with-lilly",
        "pubDate": "2021-04-15 11:33:00"
    },
    {
        "filename": "record-breaking-sales-of-24-8bn-by-2021-predicted-for-pfizer-biontech-s-vaccine.json",
        "title": "Record-breaking sales of $24.8bn by 2021 predicted for Pfizer/BioNTech\u00e2\u0080\u0099s vaccine",
        "description": "Record-breaking sales of $24.8bn by 2021 predicted for Pfizer/BioNTech\u00e2\u0080\u0099s vaccine",
        "link": "https://www.thepharmaletter.com/article/record-breaking-sales-of-24-8bn-by-2021-predicted-for-pfizer-biontech-s-vaccine",
        "pubDate": "2021-04-15 11:05:00"
    },
    {
        "filename": "counterfeit-drugs-threat-to-india-s-self-reliant-model.json",
        "title": "Counterfeit drugs: threat to India\u00e2\u0080\u0099s self-reliant model",
        "description": "Counterfeit drugs: threat to India\u00e2\u0080\u0099s self-reliant model",
        "link": "https://www.thepharmaletter.com/article/counterfeit-drugs-threat-to-india-s-self-reliant-model",
        "pubDate": "2021-04-14 16:26:00"
    },
    {
        "filename": "tango-therapeutics-to-go-public-via-merger-with-bctg-acquisition.json",
        "title": "Tango Therapeutics to go public via merger with BCTG Acquisition",
        "description": "Tango Therapeutics to go public via merger with BCTG Acquisition",
        "link": "https://www.thepharmaletter.com/article/tango-therapeutics-to-go-public-via-merger-with-bctg-acquisition",
        "pubDate": "2021-04-14 15:50:00"
    },
    {
        "filename": "us-appeals-court-upholds-ftc-s-opinion-against-impax-labs.json",
        "title": "US appeals court upholds FTC\u00e2\u0080\u0099s opinion against Impax Labs",
        "description": "US appeals court upholds FTC\u00e2\u0080\u0099s opinion against Impax Labs",
        "link": "https://www.thepharmaletter.com/article/us-appeals-court-upholds-ftc-s-opinion-against-impax-labs",
        "pubDate": "2021-04-14 15:03:00"
    },
    {
        "filename": "romark-to-seek-eua-for-antiviral-compound-to-treat-covid-19.json",
        "title": "Romark to seek EUA for antiviral compound to treat COVID-19",
        "description": "Privately-held Romark Laboratories has announced initial results from a Phase III trial of its oral investigational antiviral compound NT-300 (nitazoxanide exte",
        "link": "https://www.thepharmaletter.com/article/romark-to-seek-eua-for-antiviral-compound-to-treat-covid-19",
        "pubDate": "2021-04-14 15:00:00"
    },
    {
        "filename": "china-nod-for-tagrisso-on-early-stage-egfr-mutated-lung-cancer.json",
        "title": "China nod for Tagrisso on early-stage EGFR-mutated lung cancer",
        "description": "China nod for Tagrisso on early-stage EGFR-mutated lung cancer",
        "link": "https://www.thepharmaletter.com/article/china-nod-for-tagrisso-on-early-stage-egfr-mutated-lung-cancer",
        "pubDate": "2021-04-14 14:13:00"
    },
    {
        "filename": "msf-keeps-up-pressure-on-insulin-access-as-who-launches-global-diabetes-compact.json",
        "title": "MSF keeps up pressure on insulin access as WHO launches Global Diabetes Compact",
        "description": "The World Health Organization (WHO) is hopeful that its Global Diabetes Compact will help to bring the right care to all who need it as well as boosting efforts",
        "link": "https://www.thepharmaletter.com/article/msf-keeps-up-pressure-on-insulin-access-as-who-launches-global-diabetes-compact",
        "pubDate": "2021-04-14 12:47:00"
    },
    {
        "filename": "india-seeks-import-of-covid-19-vaccines-move-to-bolster-domestic-producers.json",
        "title": "India seeks import of COVID-19 vaccines; move to bolster domestic producers",
        "description": "India seeks import of COVID-19 vaccines; move to bolster domestic producers",
        "link": "https://www.thepharmaletter.com/article/india-seeks-import-of-covid-19-vaccines-move-to-bolster-domestic-producers",
        "pubDate": "2021-04-14 12:23:00"
    },
    {
        "filename": "spark-thera-collaborates-with-senti-bio.json",
        "title": "Spark Thera collaborates with Senti Bio",
        "description": "Spark Thera collaborates with Senti Bio",
        "link": "https://www.thepharmaletter.com/article/spark-thera-collaborates-with-senti-bio",
        "pubDate": "2021-04-14 11:49:00"
    },
    {
        "filename": "moderna-shows-lasting-vaccine-efficacy-and-hope-for-boosters.json",
        "title": "Moderna shows lasting vaccine efficacy and hope for boosters",
        "description": "East Coast, USA-based mRNA specialist Moderna has presented positive clinical trial news from its coronavirus vaccine program.",
        "link": "https://www.thepharmaletter.com/article/moderna-shows-lasting-vaccine-efficacy-and-hope-for-boosters",
        "pubDate": "2021-04-14 11:40:00"
    },
    {
        "filename": "hemogenyx-goes-it-alone-with-aml-targeting-antibody.json",
        "title": "Hemogenyx goes it alone with AML-targeting antibody",
        "description": "London-listed blood disease specialist Hemogenyx Pharmaceuticals (LSE: HEMO) has provided an update on the development of its lead product candidate, a CDX bisp",
        "link": "https://www.thepharmaletter.com/article/hemogenyx-goes-it-alone-with-aml-targeting-antibody",
        "pubDate": "2021-04-14 11:01:00"
    },
    {
        "filename": "fda-accelerated-approval-for-trodelvy-in-advanced-urothelial-cancer.json",
        "title": "FDA accelerated approval for Trodelvy in advanced urothelial cancer",
        "description": "FDA accelerated approval for Trodelvy in advanced urothelial cancer",
        "link": "https://www.thepharmaletter.com/article/fda-accelerated-approval-for-trodelvy-in-advanced-urothelial-cancer",
        "pubDate": "2021-04-14 10:57:00"
    },
    {
        "filename": "innovent-and-lilly-s-tyvyt-meets-endpoint-in-phase-iii-lung-cancer-trial.json",
        "title": "Innovent and Lilly\u00e2\u0080\u0099s Tyvyt meets endpoint in Phase III lung cancer trial",
        "description": NaN,
        "link": "https://www.thepharmaletter.com/article/innovent-and-lilly-s-tyvyt-meets-endpoint-in-phase-iii-lung-cancer-trial",
        "pubDate": "2021-04-13 16:42:00"
    },
    {
        "filename": "repertoire-immune-bags-189-million-financing.json",
        "title": "Repertoire Immune bags $189 million financing",
        "description": "Repertoire Immune bags $189 million financing",
        "link": "https://www.thepharmaletter.com/article/repertoire-immune-bags-189-million-financing",
        "pubDate": "2021-04-13 16:31:00"
    },
    {
        "filename": "actimed-out-licenses-s-oxprenolol-to-faraday-pharma.json",
        "title": "Actimed out-licenses S-oxprenolol to Faraday Pharma",
        "description": "Actimed out-licenses S-oxprenolol to Faraday Pharma",
        "link": "https://www.thepharmaletter.com/article/actimed-out-licenses-s-oxprenolol-to-faraday-pharma",
        "pubDate": "2021-04-13 15:55:00"
    },
    {
        "filename": "beigene-unveils-new-phase-iii-data-for-tislelizumab.json",
        "title": "BeiGene unveils new Phase III data for tislelizumab",
        "description": "BeiGene unveils new Phase III data for tislelizumab",
        "link": "https://www.thepharmaletter.com/article/beigene-unveils-new-phase-iii-data-for-tislelizumab",
        "pubDate": "2021-04-13 14:13:00"
    },
    {
        "filename": "cdc-and-fda-recommend-pausing-j-j-covid-19-vaccine-use.json",
        "title": "CDC and FDA recommend pausing J&J COVID-19 vaccine use",
        "description": "Johnson & Johnson\u00e2\u0080\u0099s jab is the latest COVID-19 vaccine to be linked to rare cases of blood clots, prompting US health agencies to recommend pausing its use pend",
        "link": "https://www.thepharmaletter.com/article/cdc-and-fda-recommend-pausing-j-j-covid-19-vaccine-use",
        "pubDate": "2021-04-13 13:16:00"
    },
    {
        "filename": "india-approves-russia-s-sputnik-v-coronavirus-vaccine.json",
        "title": "India approves Russia's Sputnik V coronavirus vaccine",
        "description": "Russia\u00e2\u0080\u0099s homegrown coronavirus vaccine, Sputnik V, has won approval in India, making it the third vaccine against the disease to be approved in the country.",
        "link": "https://www.thepharmaletter.com/article/india-approves-russia-s-sputnik-v-coronavirus-vaccine",
        "pubDate": "2021-04-13 12:35:00"
    },
    {
        "filename": "sage-and-biogen-shares-dip-on-essential-tremor-drug-s-questionable-tolerability.json",
        "title": "Sage and Biogen shares dip on essential tremor drug\u00e2\u0080\u0099s questionable tolerability",
        "description": "Both companies in the CNS partnership of Sage Therapeutics (Nasdaq: SAGE) and Biogen (Nasdaq: BIIB) closed more than 2% lower on Monday.",
        "link": "https://www.thepharmaletter.com/article/sage-and-biogen-shares-dip-on-essential-tremor-drug-s-questionable-tolerability",
        "pubDate": "2021-04-13 12:14:00"
    },
    {
        "filename": "russia-s-biocad-to-compete-with-biogen-and-roche-with-new-drug-for-sma.json",
        "title": "Russia\u00e2\u0080\u0099s Biocad to compete with Biogen and Roche with new drug for SMA",
        "description": "Russia\u00e2\u0080\u0099s Biocad to compete with Biogen and Roche with new drug for SMARussia\u00e2\u0080\u0099s Biocad to compete with Biogen and Roche with new drug for SMA",
        "link": "https://www.thepharmaletter.com/article/russia-s-biocad-to-compete-with-biogen-and-roche-with-new-drug-for-sma",
        "pubDate": "2021-04-13 11:52:00"
    },
    {
        "filename": "novo-nordisk-to-launch-new-production-of-fast-acting-insulin-at-its-russian-plant-in-june.json",
        "title": "Novo Nordisk to launch new production of fast-acting insulin at its Russian plant in June",
        "description": "Novo Nordisk to launch new production of fast-acting insulin at its Russian plant in June",
        "link": "https://www.thepharmaletter.com/article/novo-nordisk-to-launch-new-production-of-fast-acting-insulin-at-its-russian-plant-in-june",
        "pubDate": "2021-04-13 10:26:00"
    },
    {
        "filename": "merck-advances-atr-inhibitor-berzosertib-in-small-cell-lung-cancer.json",
        "title": "Merck advances ATR inhibitor berzosertib in small cell lung cancer",
        "description": "Merck advances ATR inhibitor berzosertib in small cell lung cancer",
        "link": "https://www.thepharmaletter.com/article/merck-advances-atr-inhibitor-berzosertib-in-small-cell-lung-cancer",
        "pubDate": "2021-04-13 10:04:00"
    },
    {
        "filename": "icer-to-incorporate-rwe-into-assessment-of-hae-drugs.json",
        "title": "ICER to incorporate RWE into assessment of HAE drugs",
        "description": "The Institute for Clinical and Economic Review (ICER) has announced that it is using observational real-world evidence (RWE) to update its 2018 assessment of th",
        "link": "https://www.thepharmaletter.com/article/icer-to-incorporate-rwe-into-assessment-of-hae-drugs",
        "pubDate": "2021-04-12 15:53:00"
    },
    {
        "filename": "us-president-s-discretionary-funding-request-includes-new-research-agency.json",
        "title": "US President\u00e2\u0080\u0099s discretionary funding request includes new research agency",
        "description": "US President\u00e2\u0080\u0099s discretionary funding request includes new research agency",
        "link": "https://www.thepharmaletter.com/article/us-president-s-discretionary-funding-request-includes-new-research-agency",
        "pubDate": "2021-04-12 15:00:00"
    },
    {
        "filename": "tollys-appoints-head-of-clinical-development.json",
        "title": "Tollys appoints head of clinical development",
        "description": "Tollys appoints head of clinical development",
        "link": "https://www.thepharmaletter.com/article/tollys-appoints-head-of-clinical-development",
        "pubDate": "2021-04-12 13:40:00"
    },
    {
        "filename": "dare-19-phase-iii-trial-for-farxiga-in-covid-19-misses-endpoint.json",
        "title": "DARE-19 Phase III trial for Farxiga in COVID-19 misses endpoint",
        "description": "DARE-19 Phase III trial for Farxiga in COVID-19 misses endpoint",
        "link": "https://www.thepharmaletter.com/article/dare-19-phase-iii-trial-for-farxiga-in-covid-19-misses-endpoint",
        "pubDate": "2021-04-12 11:35:00"
    },
    {
        "filename": "phase-iii-data-confirm-potency-of-roche-coronavirus-treatment.json",
        "title": "Phase III data confirm potency of Roche coronavirus treatment",
        "description": "Swiss pharma giant Roche has confirmed positive results from the Phase III REGN-COV 2069 trial, which tests an investigational antibody cocktail in COVID-19.",
        "link": "https://www.thepharmaletter.com/article/phase-iii-data-confirm-potency-of-roche-coronavirus-treatment",
        "pubDate": "2021-04-12 10:55:00"
    },
    {
        "filename": "c4x-discovery-inks-lucrative-c4xd-oral-il-17a-inhibitor-deal.json",
        "title": "C4X Discovery inks lucrative C4XD oral IL-17A inhibitor deal",
        "description": "C4X Discovery inks lucrative C4XD oral IL-17A inhibitor deal",
        "link": "https://www.thepharmaletter.com/article/c4x-discovery-inks-lucrative-c4xd-oral-il-17a-inhibitor-deal",
        "pubDate": "2021-04-12 10:35:00"
    },
    {
        "filename": "aliqopa-combo-shows-significant-pfs-in-non-hodgkin-s-lymphoma.json",
        "title": "Aliqopa combo shows significant PFS in non-Hodgkin's lymphoma",
        "description": "Aliqopa combo shows significant PFS in non-Hodgkin's lymphoma",
        "link": "https://www.thepharmaletter.com/article/aliqopa-combo-shows-significant-pfs-in-non-hodgkin-s-lymphoma",
        "pubDate": "2021-04-12 10:14:00"
    },
    {
        "filename": "phrma-comments-on-nist-in-effort-to-safeguard-ip-protections.json",
        "title": "PhRMA comments on NIST in effort to safeguard IP protections",
        "description": "PhRMA comments on NIST in effort to safeguard IP protections",
        "link": "https://www.thepharmaletter.com/article/phrma-comments-on-nist-in-effort-to-safeguard-ip-protections",
        "pubDate": "2021-04-12 10:13:00"
    },
    {
        "filename": "look-back-at-pharma-news-in-the-week-to-april-9-2021.json",
        "title": "Look back at pharma news in the week to April 9, 2021",
        "description": "Look back at pharma news in the week to April 9, 2021",
        "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-april-9-2021",
        "pubDate": "2021-04-11 10:48:00"
    },
    {
        "filename": "sanofi-snaps-up-us-biotech-to-expand-i-o-portfolio.json",
        "title": "Sanofi snaps up US biotech to expand I-O portfolio",
        "description": "Sanofi snaps up US biotech to expand I-O portfolio",
        "link": "https://www.thepharmaletter.com/article/sanofi-snaps-up-us-biotech-to-expand-i-o-portfolio",
        "pubDate": "2021-04-10 15:59:00"
    },
    {
        "filename": "genmab-and-seagen-s-bla-for-tisotumab-vedotin-accepted-for-priority-review.json",
        "title": "Genmab and Seagen\u00e2\u0080\u0099s BLA for tisotumab vedotin accepted for priority review",
        "description": "Genmab and Seagen\u00e2\u0080\u0099s BLA for tisotumab vedotin accepted for priority review",
        "link": "https://www.thepharmaletter.com/article/genmab-and-seagen-s-bla-for-tisotumab-vedotin-accepted-for-priority-review",
        "pubDate": "2021-04-10 14:57:00"
    },
    {
        "filename": "celcuity-granted-exclusive-rights-to-pfizer-s-gedatolisib.json",
        "title": "Celcuity granted exclusive rights to Pfizer\u00e2\u0080\u0099s gedatolisib",
        "description": "US biotech Celcuity has entered into a global licensing agreement with Pfizer (NYSE:PFE) to acquire exclusive rights to the US pharma giant\u00e2\u0080\u0099s gedatolisib, a Pha",
        "link": "https://www.thepharmaletter.com/article/celcuity-granted-exclusive-rights-to-pfizer-s-gedatolisib",
        "pubDate": "2021-04-09 17:58:00"
    },
    {
        "filename": "market-frets-over-deficiencies-in-teplizumab-submission.json",
        "title": "Market frets over \"deficiencies\" in teplizumab submission",
        "description": "Stock in Provention Bio fell 35% ahead of trading on Friday, after the firm reported a regulatory setback related to its novel diabetes med teplizumab.",
        "link": "https://www.thepharmaletter.com/article/market-frets-over-deficiencies-in-teplizumab-submission",
        "pubDate": "2021-04-09 16:40:00"
    },
    {
        "filename": "down-syndrome-drug-development-given-six-million-euros-ec-grant.json",
        "title": "Down syndrome drug development given six million euros EC grant",
        "description": "AELIS FARMA, a privately-held French biotech specializing in the treatment of brain disorders, has announced a boost for the Improving Cognition in Down Syndrom",
        "link": "https://www.thepharmaletter.com/article/down-syndrome-drug-development-given-six-million-euros-ec-grant",
        "pubDate": "2021-04-09 16:32:00"
    },
    {
        "filename": "ema-prac-investigating-safety-of-more-covid-19-vaccines.json",
        "title": "EMA/PRAC investigating safety of more COVID-19 vaccines",
        "description": "EMA/PRAC investigating safety of more COVID-19 vaccines",
        "link": "https://www.thepharmaletter.com/article/ema-prac-investigating-safety-of-more-covid-19-vaccines",
        "pubDate": "2021-04-09 15:14:00"
    },
    {
        "filename": "therapeuticsmd-and-theramex-gain-uk-and-belgium-approval-for-hrt-therapy.json",
        "title": "TherapeuticsMD and Theramex gain UK and Belgium approval for HRT therapy",
        "description": "TherapeuticsMD and Theramex gain UK and Belgium approval for HRT therapy",
        "link": "https://www.thepharmaletter.com/article/therapeuticsmd-and-theramex-gain-uk-and-belgium-approval-for-hrt-therapy",
        "pubDate": "2021-04-09 12:31:00"
    },
    {
        "filename": "bms-present-mixed-opdivo-and-yervoy-data-in-escc.json",
        "title": "BMS present mixed Opdivo and Yervoy data in ESCC",
        "description": "Bristol Myers Squibb has announced topline results from the Phase III CheckMate -648 trial evaluating Opdivo (nivolumab) plus chemotherapy or alongside Yervoy (",
        "link": "https://www.thepharmaletter.com/article/bms-present-mixed-opdivo-and-yervoy-data-in-escc",
        "pubDate": "2021-04-09 11:53:00"
    },
    {
        "filename": "baricitinib-misses-goal-in-phase-iii-hospitalized-covid-19-patient-study.json",
        "title": "Baricitinib misses goal in Phase III hospitalized COVID-19 patient study",
        "description": "Baricitinib misses goal in Phase III hospitalized COVID-19 patient study",
        "link": "https://www.thepharmaletter.com/article/baricitinib-misses-goal-in-phase-iii-hospitalized-covid-19-patient-study",
        "pubDate": "2021-04-09 10:58:00"
    },
    {
        "filename": "roadblock-for-ryvu-s-novel-kinase-blocker.json",
        "title": "Roadblock for Ryvu's novel kinase blocker",
        "description": "In the USA, a partial clinical hold has been placed on a Phase Ib trial of RVU120, being undertaken by Krakow-based Ryvu Therapeutics.",
        "link": "https://www.thepharmaletter.com/article/roadblock-for-ryvu-s-novel-kinase-blocker",
        "pubDate": "2021-04-09 10:25:00"
    },
    {
        "filename": "sales-forecast-for-novavax-covid-19-vaccine.json",
        "title": "Sales forecast for Novavax\u00e2\u0080\u0099 COVID-19 vaccine",
        "description": "Sales forecast for Novavax\u00e2\u0080\u0099 COVID-19 vaccine",
        "link": "https://www.thepharmaletter.com/article/sales-forecast-for-novavax-covid-19-vaccine",
        "pubDate": "2021-04-09 10:07:00"
    },
    {
        "filename": "ventus-therapeutics-closes-100-million-series-b-financing.json",
        "title": "Ventus Therapeutics closes $100 million Series B financing",
        "description": "Ventus Therapeutics closes $100 million Series B financing",
        "link": "https://www.thepharmaletter.com/article/ventus-therapeutics-closes-100-million-series-b-financing",
        "pubDate": "2021-04-08 16:21:00"
    },
    {
        "filename": "pierre-fabre-and-valenzabio-collaborate-on-anti-igf-1r-antibody-for-ted.json",
        "title": "Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TED",
        "description": "Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TED",
        "link": "https://www.thepharmaletter.com/article/pierre-fabre-and-valenzabio-collaborate-on-anti-igf-1r-antibody-for-ted",
        "pubDate": "2021-04-08 15:46:00"
    },
    {
        "filename": "novartis-now-bags-uk-license-for-kesimpta.json",
        "title": "Novartis now bags UK license for Kesimpta",
        "description": "Novartis now bags UK license for Kesimpta",
        "link": "https://www.thepharmaletter.com/article/novartis-now-bags-uk-license-for-kesimpta",
        "pubDate": "2021-04-08 15:07:00"
    },
    {
        "filename": "beigene-gains-nmpa-approval-for-new-biologics-facility-in-guangzhou.json",
        "title": "BeiGene gains NMPA approval for new biologics facility in Guangzhou",
        "description": "BeiGene gains NMPA approval for new biologics facility in Guangzhou",
        "link": "https://www.thepharmaletter.com/article/beigene-gains-nmpa-approval-for-new-biologics-facility-in-guangzhou",
        "pubDate": "2021-04-08 13:58:00"
    },
    {
        "filename": "long-term-results-on-oxbryta-published-in-journal.json",
        "title": "Long-term results on Oxbryta published in journal",
        "description": "US biopharma Global Blood Therapeutics has announced that The Lancet Haematology has published the complete analysis of 72-week data from the Phase III HOPE Stu",
        "link": "https://www.thepharmaletter.com/article/long-term-results-on-oxbryta-published-in-journal",
        "pubDate": "2021-04-08 12:42:00"
    },
    {
        "filename": "india-set-to-see-drug-price-hikes.json",
        "title": "India set to see drug price hikes",
        "description": "India set to see drug price hikes",
        "link": "https://www.thepharmaletter.com/article/india-set-to-see-drug-price-hikes",
        "pubDate": "2021-04-08 12:01:00"
    },
    {
        "filename": "rebranded-hutchmed-to-launch-in-london-with-100-million.json",
        "title": "Rebranded Hutchmed secures $100 million investment",
        "description": "Hutchison China MediTech, also known as Hutchmed, has announced a private placement of $100 million of funds from Baring Private Equity Asia (BPEA).",
        "link": "https://www.thepharmaletter.com/article/rebranded-hutchmed-to-launch-in-london-with-100-million",
        "pubDate": "2021-04-08 11:38:00"
    },
    {
        "filename": "us-nih-to-investigate-allergic-reactions-after-mrna-based-vaccines.json",
        "title": "US NIH to investigate allergic reactions after mRNA-based vaccines",
        "description": "In the USA, the National Institutes of Health (NIH) is to initiate a Phase II trial to investigate the causes of certain allergic reactions to mRNA-based vaccin",
        "link": "https://www.thepharmaletter.com/article/us-nih-to-investigate-allergic-reactions-after-mrna-based-vaccines",
        "pubDate": "2021-04-08 11:31:00"
    },
    {
        "filename": "zydus-cadila-gets-us-fda-nod-for-imbruvica-generic.json",
        "title": "Zydus Cadila gets US FDA nod for Imbruvica generic",
        "description": "Zydus Cadila gets US FDA nod for Imbruvica generic",
        "link": "https://www.thepharmaletter.com/article/zydus-cadila-gets-us-fda-nod-for-imbruvica-generic",
        "pubDate": "2021-04-08 11:19:00"
    },
    {
        "filename": "fda-grants-regular-approval-for-trodelvy.json",
        "title": "FDA grants regular approval for Trodelvy",
        "description": "FDA grants regular approval for Trodelvy",
        "link": "https://www.thepharmaletter.com/article/fda-grants-regular-approval-for-trodelvy",
        "pubDate": "2021-04-08 10:32:00"
    },
    {
        "filename": "blockchain-and-the-covid-19-vaccine-rollout.json",
        "title": "Blockchain and the COVID-19 vaccine rollout",
        "description": "Hannah Schofield, associate at Hogan Lovells, considers the option of utilizing blockchain technology for accurate tracking and monitoring in an Expert View pie",
        "link": "https://www.thepharmaletter.com/article/blockchain-and-the-covid-19-vaccine-rollout",
        "pubDate": "2021-04-07 18:10:00"
    },
    {
        "filename": "ema-finds-possible-link-of-astrazeneca-s-covid-19-vaccine-with-rare-blood-clots.json",
        "title": "EMA finds possible link of AstraZeneca\u00e2\u0080\u0099s COVID-19 vaccine with rare blood clots",
        "description": "EMA finds possible link of AstraZeneca\u00e2\u0080\u0099s COVID-19 vaccine with rare blood clots",
        "link": "https://www.thepharmaletter.com/article/ema-finds-possible-link-of-astrazeneca-s-covid-19-vaccine-with-rare-blood-clots",
        "pubDate": "2021-04-07 16:20:00"
    },
    {
        "filename": "antibodies-persist-six-months-after-second-moderna-covid-19-jab.json",
        "title": "Antibodies persist six months after second Moderna COVID-19 jab",
        "description": "Antibody activity remained high in all age groups beyond six months after the second dose of Moderna\u00e2\u0080\u0099s COVID-19 vaccine, according to research published in the ",
        "link": "https://www.thepharmaletter.com/article/antibodies-persist-six-months-after-second-moderna-covid-19-jab",
        "pubDate": "2021-04-07 16:01:00"
    },
    {
        "filename": "akili-links-with-us-academia-on-akl-t01-as-treatment-for-covid-brain-fog.json",
        "title": "Akili links with US academia on AKL-T01 as treatment for \u00e2\u0080\u009cCOVID brain fog\u00e2\u0080\u009d",
        "description": "Akili links with US academia on AKL-T01 as treatment for \u00e2\u0080\u009cCOVID brain fog\u00e2\u0080\u009d",
        "link": "https://www.thepharmaletter.com/article/akili-links-with-us-academia-on-akl-t01-as-treatment-for-covid-brain-fog",
        "pubDate": "2021-04-07 15:18:00"
    },
    {
        "filename": "psychedelics-specialist-starts-phase-iia-test-of-lead-candidate.json",
        "title": "Psychedelics specialist starts Phase IIa test of lead candidate",
        "description": "A Phase IIa study has been initiated for RL-007, lead candidate of Recognify Life Sciences, part of Berlin-based biotech Atai Life Sciences.",
        "link": "https://www.thepharmaletter.com/article/psychedelics-specialist-starts-phase-iia-test-of-lead-candidate",
        "pubDate": "2021-04-07 14:49:00"
    },
    {
        "filename": "fibrogen-admits-false-safety-data-used-for-roxadustat.json",
        "title": "FibroGen admits false safety data presented for roxadustat",
        "description": "FibroGen admits false safety data used for roxadustat",
        "link": "https://www.thepharmaletter.com/article/fibrogen-admits-false-safety-data-used-for-roxadustat",
        "pubDate": "2021-04-07 14:12:00"
    },
    {
        "filename": "john-robinson-jumps-from-pfizer-to-become-cogent-cso.json",
        "title": "John Robinson jumps from Pfizer to become Cogent CSO",
        "description": NaN,
        "link": "https://www.thepharmaletter.com/article/john-robinson-jumps-from-pfizer-to-become-cogent-cso",
        "pubDate": "2021-04-07 12:40:00"
    },
    {
        "filename": "artios-links-up-with-novartis-on-ddr-cancer-therapies.json",
        "title": "Artios links up with Novartis on DDR cancer therapies",
        "description": "Artios links up with Novartis on DDR cancer therapies",
        "link": "https://www.thepharmaletter.com/article/artios-links-up-with-novartis-on-ddr-cancer-therapies",
        "pubDate": "2021-04-07 12:12:00"
    },
    {
        "filename": "oxford-pauses-pediatric-trial-of-astrazeneca-vaccine.json",
        "title": "Oxford pauses pediatric trial of AstraZeneca vaccine",
        "description": "Scientists at The University of Oxford have paused a UK-based pediatric trial testing Vaxzevria, the group\u00e2\u0080\u0099s AstraZeneca-partnered coronavirus vaccine.",
        "link": "https://www.thepharmaletter.com/article/oxford-pauses-pediatric-trial-of-astrazeneca-vaccine",
        "pubDate": "2021-04-07 11:30:00"
    },
    {
        "filename": "sanofi-global-health-set-up-to-provide-30-essential-meds-to-poorest-countries.json",
        "title": "Sanofi Global Health set up to provide 30 essential meds to poorest countries",
        "description": "Sanofi Global Health set up to provide 30 essential meds to poorest countries",
        "link": "https://www.thepharmaletter.com/article/sanofi-global-health-set-up-to-provide-30-essential-meds-to-poorest-countries",
        "pubDate": "2021-04-07 11:10:00"
    },
    {
        "filename": "positive-data-for-valneva-s-covid-19-vaccine-candidate-vla2001.json",
        "title": "Positive data for Valneva\u00e2\u0080\u0099s COVID-19 vaccine candidate, VLA2001",
        "description": "Positive data for Valneva\u00e2\u0080\u0099s COVID-19 vaccine candidate, VLA2001",
        "link": "https://www.thepharmaletter.com/article/positive-data-for-valneva-s-covid-19-vaccine-candidate-vla2001",
        "pubDate": "2021-04-07 10:26:00"
    },
    {
        "filename": "crucial-brazil-decision-due-on-amending-national-patent-law.json",
        "title": "Crucial Brazil decision due on amending national patent law",
        "description": "The Brazilian Supreme Court of Justice is expected to deliver a potentially groundbreaking verdict on the constitutionality of a provision in the country\u00e2\u0080\u0099s inte",
        "link": "https://www.thepharmaletter.com/article/crucial-brazil-decision-due-on-amending-national-patent-law",
        "pubDate": "2021-04-06 17:25:00"
    },
    {
        "filename": "russian-drugmakers-confirm-plans-for-localization-of-foreign-vaccines.json",
        "title": "Russian drugmakers confirm plans for localization of foreign vaccines",
        "description": "Russian drugmakers confirm plans for localization of foreign vaccines",
        "link": "https://www.thepharmaletter.com/article/russian-drugmakers-confirm-plans-for-localization-of-foreign-vaccines",
        "pubDate": "2021-04-06 16:55:00"
    },
    {
        "filename": "icer-reviews-price-of-new-multiple-myeloma-treatments.json",
        "title": "ICER reviews price of new multiple myeloma treatments",
        "description": "The Institute for Clinical and Economic Review (ICER) has released an evidence report comparing clinical effectiveness and value of three new treatments targeti",
        "link": "https://www.thepharmaletter.com/article/icer-reviews-price-of-new-multiple-myeloma-treatments",
        "pubDate": "2021-04-06 16:24:00"
    },
    {
        "filename": "sterling-pharma-solutions-confirms-acquisition-of-adc-bio.json",
        "title": "Sterling Pharma Solutions confirms acquisition of ADC Bio",
        "description": "Sterling Pharma Solutions confirms acquisition of ADC Bio",
        "link": "https://www.thepharmaletter.com/article/sterling-pharma-solutions-confirms-acquisition-of-adc-bio",
        "pubDate": "2021-04-06 16:07:00"
    },
    {
        "filename": "uk-patients-to-benefit-from-five-minute-breast-cancer-treatment.json",
        "title": "UK patients to benefit from five-minute breast cancer treatment",
        "description": "UK patients to benefit from five-minute breast cancer treatment",
        "link": "https://www.thepharmaletter.com/article/uk-patients-to-benefit-from-five-minute-breast-cancer-treatment",
        "pubDate": "2021-04-06 13:44:00"
    },
    {
        "filename": "russia-s-pharma-to-accelerate-expansion-into-central-and-south-america.json",
        "title": "Russia\u00e2\u0080\u0099s pharma to accelerate expansion into Central and South America",
        "description": "Russia\u00e2\u0080\u0099s pharma to accelerate expansion into Central and South America",
        "link": "https://www.thepharmaletter.com/article/russia-s-pharma-to-accelerate-expansion-into-central-and-south-america",
        "pubDate": "2021-04-06 12:02:00"
    },
    {
        "filename": "acadia-to-take-issue-with-fda-over-crl-for-nuplazid-sbla.json",
        "title": "Acadia to take issue with FDA over CRL for Nuplazid sBLA",
        "description": "Acadia to take issue with FDA over CRL for Nuplazid sBLA",
        "link": "https://www.thepharmaletter.com/article/acadia-to-take-issue-with-fda-over-crl-for-nuplazid-sbla",
        "pubDate": "2021-04-06 10:56:00"
    },
    {
        "filename": "more-snakes-added-to-label-for-antivenom-product.json",
        "title": "More snakes added to label for antivenom product",
        "description": "Tennessee, USA-based firm Rare Disease Therapeutics (RDT) has secured a new expanded indication for its antivenom product Anavip (crotalidae immune).",
        "link": "https://www.thepharmaletter.com/article/more-snakes-added-to-label-for-antivenom-product",
        "pubDate": "2021-04-06 10:44:00"
    },
    {
        "filename": "cidara-inks-up-to-780-million-deal-for-antiviral-conjugates.json",
        "title": "Cidara inks up to $780 million deal for antiviral conjugates",
        "description": "Cidara inks up to $780 million deal for antiviral conjugates",
        "link": "https://www.thepharmaletter.com/article/cidara-inks-up-to-780-million-deal-for-antiviral-conjugates",
        "pubDate": "2021-04-06 10:26:00"
    },
    {
        "filename": "mncs-in-fast-changing-china-hkex-expects-spac-soon.json",
        "title": "MNCs in fast-changing China; HKEX expects SPAC soon",
        "description": "MNCs in fast-changing China; HKEX expects SPAC soon",
        "link": "https://www.thepharmaletter.com/article/mncs-in-fast-changing-china-hkex-expects-spac-soon",
        "pubDate": "2021-04-06 10:24:00"
    },
    {
        "filename": "fda-approves-qelbree-to-treat-adhd.json",
        "title": "FDA approves Qelbree to treat ADHD",
        "description": "FDA approves Qelbree to treat ADHD",
        "link": "https://www.thepharmaletter.com/article/fda-approves-qelbree-to-treat-adhd",
        "pubDate": "2021-04-06 10:23:00"
    },
    {
        "filename": "astellas-terminates-distribution-deal-with-toa-eiyo.json",
        "title": "Astellas terminates distribution deal with Toa Eiyo",
        "description": "Astellas terminates distribution deal with Toa Eiyo",
        "link": "https://www.thepharmaletter.com/article/astellas-terminates-distribution-deal-with-toa-eiyo",
        "pubDate": "2021-04-06 10:22:00"
    },
    {
        "filename": "covig-19-plasma-alliance-s-immunoglobulin-trial-misses-goals.json",
        "title": "CoVIg-19 Plasma Alliance\u00e2\u0080\u0099s immunoglobulin trial misses goals",
        "description": "CoVIg-19 Plasma Alliance\u00e2\u0080\u0099s immunoglobulin trial misses goals",
        "link": "https://www.thepharmaletter.com/article/covig-19-plasma-alliance-s-immunoglobulin-trial-misses-goals",
        "pubDate": "2021-04-04 14:48:00"
    },
    {
        "filename": "look-back-at-pharma-news-in-the-week-to-april-2-2021.json",
        "title": "Look back at pharma news in the week to April 2, 2021",
        "description": "Look back at pharma news in the week to April 2, 2021",
        "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-april-2-2021",
        "pubDate": "2021-04-04 11:33:00"
    },
    {
        "filename": "azurrx-biopharma-slumps-as-option-2-trial-of-ms1819-in-cf-fails.json",
        "title": "AzurRx BioPharma slumps as OPTION 2 trial of MS1819 in CF fails",
        "description": "AzurRx BioPharma slumps as OPTION 2 trial of MS1819 in CF fails",
        "link": "https://www.thepharmaletter.com/article/azurrx-biopharma-slumps-as-option-2-trial-of-ms1819-in-cf-fails",
        "pubDate": "2021-04-03 15:56:00"
    },
    {
        "filename": "j-j-hits-snag-as-covid-19-vaccine-contractor-failed-quality-standards.json",
        "title": "J&J hits snag as COVID-19 vaccine contractor failed quality standards",
        "description": "J&J hits snag as COVID-19 vaccine contractor failed quality standards",
        "link": "https://www.thepharmaletter.com/article/j-j-hits-snag-as-covid-19-vaccine-contractor-failed-quality-standards",
        "pubDate": "2021-04-03 15:06:00"
    },
    {
        "filename": "fda-approves-sarclisa-with-kyprolis-for-multiple-myeloma.json",
        "title": "FDA approves Sarclisa with Kyprolis for multiple myeloma",
        "description": "FDA approves Sarclisa with Kyprolis for multiple myeloma",
        "link": "https://www.thepharmaletter.com/article/fda-approves-sarclisa-with-kyprolis-for-multiple-myeloma",
        "pubDate": "2021-04-02 16:23:00"
    },
    {
        "filename": "fda-grants-a-new-indication-for-praluent.json",
        "title": "FDA grants a new indication for Praluent",
        "description": "FDA grants a new indication for Praluent",
        "link": "https://www.thepharmaletter.com/article/fda-grants-a-new-indication-for-praluent",
        "pubDate": "2021-04-02 13:37:00"
    },
    {
        "filename": "fda-breakthrough-status-for-taiho-s-futibatinib.json",
        "title": "FDA \u00e2\u0080\u0098Breakthrough\u00e2\u0080\u0099 status for Taiho\u00e2\u0080\u0099s futibatinib",
        "description": "FDA \u00e2\u0080\u0098Breakthrough\u00e2\u0080\u0099 status for Taiho\u00e2\u0080\u0099s futibatinib",
        "link": "https://www.thepharmaletter.com/article/fda-breakthrough-status-for-taiho-s-futibatinib",
        "pubDate": "2021-04-02 12:16:00"
    },
    {
        "filename": "gsk-sells-royalty-rights-on-cancer-drugs-for-nearly-400-million.json",
        "title": "GSK sells royalty rights on cancer drugs for nearly $400 million",
        "description": "GSK sells royalty rights on cancer drugs for nearly $400 million",
        "link": "https://www.thepharmaletter.com/article/gsk-sells-royalty-rights-on-cancer-drugs-for-nearly-400-million",
        "pubDate": "2021-04-02 11:22:00"
    },
    {
        "filename": "fortress-biotech-partner-gets-rights-to-lilly-s-qbrexza.json",
        "title": "Fortress Biotech partner gets rights to Lilly\u00e2\u0080\u0099s Qbrexza",
        "description": "Fortress Biotech partner gets rights to Lilly\u00e2\u0080\u0099s Qbrexza",
        "link": "https://www.thepharmaletter.com/article/fortress-biotech-partner-gets-rights-to-lilly-s-qbrexza",
        "pubDate": "2021-04-01 17:17:00"
    },
    {
        "filename": "uk-s-nice-recommends-ondexxya.json",
        "title": "UK\u00e2\u0080\u0099s NICE recommends Ondexxya",
        "description": "UK\u00e2\u0080\u0099s NICE recommends Ondexxya",
        "link": "https://www.thepharmaletter.com/article/uk-s-nice-recommends-ondexxya",
        "pubDate": "2021-04-01 16:05:00"
    },
    {
        "filename": "hemogenyx-updates-on-cdx-antibody-development.json",
        "title": "Hemogenyx updates on CDX antibody development",
        "description": "Hemogenyx updates on CDX antibody development",
        "link": "https://www.thepharmaletter.com/article/hemogenyx-updates-on-cdx-antibody-development",
        "pubDate": "2021-04-01 14:58:00"
    },
    {
        "filename": "ontozry-receives-ec-approval-to-treat-drug-resistant-focal-onset-seizures-in-adults.json",
        "title": "Ontozry receives EC approval to treat drug-resistant focal-onset seizures in adults",
        "description": "Privately-held Angelini Group has announced that the European Commission (EC) has granted marketing authorization for Ontozry (cenobamate) for the adjunctive tr",
        "link": "https://www.thepharmaletter.com/article/ontozry-receives-ec-approval-to-treat-drug-resistant-focal-onset-seizures-in-adults",
        "pubDate": "2021-04-01 12:40:00"
    },
    {
        "filename": "brazil-s-ansiva-raises-safety-issues-in-covaxin-production.json",
        "title": "Brazil\u00e2\u0080\u0099s ANSIVA raises safety issues in Covaxin production",
        "description": "Brazil\u00e2\u0080\u0099s ANSIVA raises safety issues in Covaxin production",
        "link": "https://www.thepharmaletter.com/article/brazil-s-ansiva-raises-safety-issues-in-covaxin-production",
        "pubDate": "2021-04-01 11:58:00"
    },
    {
        "filename": "biosimilar-bevacizumab-takes-aim-at-anti-vegf-market.json",
        "title": "Ophthalmic bevacizumab takes aim at anti-VEGF market",
        "description": "A biosimilar of Roche and Genentech\u00e2\u0080\u0099s Avastin (bevacizumab), under development for use in retinal indications, has fared well in a Phase III safety study.",
        "link": "https://www.thepharmaletter.com/article/biosimilar-bevacizumab-takes-aim-at-anti-vegf-market",
        "pubDate": "2021-04-01 11:37:00"
    },
    {
        "filename": "sanofi-to-build-new-fluzone-vaccine-facility-in-canada.json",
        "title": "Sanofi to build new Fluzone vaccine facility in Canada",
        "description": "Sanofi to build new Fluzone vaccine facility in Canada",
        "link": "https://www.thepharmaletter.com/article/sanofi-to-build-new-fluzone-vaccine-facility-in-canada",
        "pubDate": "2021-04-01 11:28:00"
    },
    {
        "filename": "sobi-secures-uk-reimbursement-nod-for-kineret.json",
        "title": "Sobi secures UK reimbursement nod for Kineret",
        "description": "Three years after launching in the UK, Swedish Orphan Biovitrum's (STO: SOBI) Kineret (anakinra) has secured a positive reimbursement decision from the country\u00e2\u0080\u0099",
        "link": "https://www.thepharmaletter.com/article/sobi-secures-uk-reimbursement-nod-for-kineret",
        "pubDate": "2021-04-01 10:47:00"
    },
    {
        "filename": "piramal-to-acquire-100-stake-in-hemmo-pharmaceuticals.json",
        "title": "Piramal to acquire 100% Stake in Hemmo Pharmaceuticals",
        "description": "Piramal to acquire 100% Stake in Hemmo Pharmaceuticals",
        "link": "https://www.thepharmaletter.com/article/piramal-to-acquire-100-stake-in-hemmo-pharmaceuticals",
        "pubDate": "2021-04-01 10:31:00"
    }
]